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ABSTRACT 
Allergic diseases are common in the growing population and have been increasing 
worldwide. Allergic sensitization, i.e. presence of Immunoglobulin E in the blood, is 
important for development of allergic disease and sensitization to foods often precedes 
sensitization to inhalant allergens. Peanut allergy is one of the most prevalent food 
allergies. It is rarely outgrown and is one of the major causes of fatal and near-fatal 
allergic reactions. However, asymptomatic peanut sensitization is common, but due to the 
risk of severe reactions, most peanut sensitized individuals have been regarded as peanut 
allergic from a clinical point of view. As a consequence, this has resulted in decreased 
quality of life due to fear of severe reactions. 
The overall aim of this thesis has been to analyse sensitization patterns to inhalant 
allergens over time, and to analyse birch pollen- and peanut-IgE antibodies and IgE to 
peanut allergen components in relation to symptoms of peanut allergy.  
The study populations in this thesis emanates from A) 4 089 children from a birth cohort 
(BAMSE) – with follow up at several time points up to eight years of age, Paper I-III and 
V, and from B) material from a clinical database, established during 2007-2010 of 237 
consecutive children with suspected peanut or tree nut allergy, and attending the 
outpatient allergy clinic at Sachs’ Children’s Hospital. Of these children, 98 were 
included in study V based on sensitization pattern to peanut allergen components. 
Paper I describes the dynamic process of sensitization to inhalant allergens. Between four 
and eight years of age, the proportion of children sensitized to any of the inhalant 
allergens tested increased from 15% to 25%. At both four and eight years the prevalence 
of IgE to birch and cat dominated, but sensitization to timothy and dog increased 
relatively more during this period. 
In Paper II we showed that children at school age, sensitized both to birch pollen and 
peanut are less likely to exhibit high IgE levels to peanut and report symptoms to peanut 
as compared to children with sensitization to peanut, but not to birch pollen. 
In Paper III IgE reactivity to peanut allergen components in 200 eight-year-old children 
was investigated. Peanut symptoms were reported in 87% of the children with IgE 
reactivity to any of the storage proteins of the peanut allergen extract Ara h 1, 2 or 3. This 
is to be compared with 17% of children with IgE reactivity to Ara h 8 (Bet v 1 
homologue), but not to Ara h 1, 2 or 3. Furthermore, symptoms were found to be more 
severe in children with Ara h 1, 2 or 3 IgE reactivity. 
Paper IV is a case report from Sachs’ Children’s Hospital, highlighting that sensitization 
to Ara h 6, homologous to Ara h 2, even in the absence of this latter protein component 
may cause severe reactions to peanut. This is likely to occur rarely. 
Paper V supports the suggestion that sensitization to Ara h 8 reflects mild OAS or peanut 
tolerance at oral peanut challenge. However, sensitization to so far unidentified 
determinants in peanut may in rare cases cause symptoms. 
In conclusion, sensitization to inhalant allergens is a dynamic process and birch 
sensitization dominates at the age of eight. Peanut component Ara h 1-3 sensitization is 
very often associated with true peanut allergy. Isolated Ara h 8 sensitization seems to 
indicate peanut tolerance. However, all peanut proteins related to IgE-mediated reactions 
may not yet have been identified and characterized. 
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1 INTRODUCTION 
 
1.1 SENSITIZATION, DEGRANULATION AND IMMUNOGLOBULIN E 
Allergic disease develops when the immune system reacts to a substance, an allergen 
which in general is harmless
1
. The allergen is usually a protein in inhaled pollen or 
animal dander, or a protein from an ingested food item. When the allergen passes the 
epithelial barrier in the lung, skin or intestine and encounters the cells of the immune 
system, a process called sensitization may take place
2
, Figure 1. The allergen is taken 
up by the antigen presenting cell (APC), which via MHC class II molecule signals to 
the naïve CD4+ T-cell to develop into a type 2 helper T cell (Th2-cell). The Th2-cell 
produces cytokines IL-4 and IL-13 and stimulates B-cells to produce allergen-specific 
Immunoglobulin E (IgE) antibodies. The secreted IgE bind to Fc receptors on mast 
cells in the connective tissue and on basophil leucocytes in the circulation. The mast 
cells and basophils are coated with specific IgE – the individual is sensitized to that 
specific allergen. At a following exposure when the same allergen enters the body, the 
allergen binds to specific IgE on the mast cell and basophil, Figure 2. Cross-linking of 
bound IgE activates the mast cell or basophil to degranulate and release inflammatory 
mediators, such as histamine, proteases and different cytokines, giving rise to vascular 
dilatation, smooth muscle contraction, inflammatory cell recruitment and tissue 
damage. Even in non-allergic individuals the mast cells are coated with IgE, but 
polyclonal IgE. Thereby, no cross-linking leading to degranulation take place
3
.  
 
  
Figure 1. Sensitization exemplified by exposure to peanut allergen. Adapted from Abbas
3
 and 
Rindsjö
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Figure 2. Exposure to peanut allergen in a peanut sensitized individual. Adapted from Abbas
3
 
and Rindsjö
2
 
 
Why some individuals produce IgE at exposure to a certain allergen, and others do not, 
is unknown. The important role of IgE in the development of allergic disease is on the 
other hand well documented
4, 5
. The IgE antibody was discovered in 1967 by two 
different research groups
6, 7
. The IgE molecule consists of two identical heavy chains 
and two identical light chains with one variable region on each chain. The four chains 
are attached together by disulphide bonds into a Y-shaped molecule. The variable 
regions make antibodies capable of binding many different allergens, including 
macromolecules and chemical compounds, and each antibody clone is specific for one 
allergen. However, IgE produced against one allergen may bind to other structurally 
similar allergens with similar epitopes (= determinants). Such binding is called cross-
reactivity
3
.  
 
1.2 ALLERGY RELATED DISEASES 
In allergic individuals, exposure to an allergen against which the individual is sensitized 
may lead to allergic symptoms. The symptoms can be immediate, within minutes, or 
rather late and occurring first after 6-24 hours via the mechanisms and mediators 
described above (1.1). Symptoms may occur from the respiratory tract (asthma, rhinitis, 
conjunctivitis, laryngeal oedema), from the oral cavity and gastrointestinal tract (OAS, 
esophagitis, nausea, vomiting, abdominal cramping, diarrhea), from the skin (eczema, 
flush, urticaria) or from the cardiovascular system (hypotension, bradycardia, syncope, 
loss of consciousness, death). Anaphylaxis is a term which is used for a multiple organ 
reaction after exposure to foods, drugs or insects stings
1, 3, 8, 9
. 
 
Food allergy, and in particular pollen-related food allergy, is the focus of this thesis. 
 
Second encounter with the allergen
MAST CELL
”Degranulation”
e.g. histamine, proteases
Allergic reaction
peanut allergen
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Clinical characteristics of the different allergic manifestations included in this thesis, 
are mainly described in the section of methods (3.2.4). 
  
1.2.1 Definitions 
1.2.1.1 Asthma 
The asthma phenotype is described by the Global Initiative for Asthma (GINA) as “a 
chronic inflammatory disorder or the airways in which many cells and cellular elements 
plays a role. The chronic inflammation is associated with airway hyper-responsiveness 
that leads to recurrent episodes of wheezing, breathlessness, chest tightness, and 
coughing, particularly at night or in the early morning. These episodes are usually 
associated with widespread, but variable, airflow obstruction within the lung that is 
often reversible either spontaneously or with treatment.”10 
 
1.2.1.2 Rhinitis 
The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines (developed in 
collaboration with the World Health Organization) defines allergic rhinitis as 
“symptoms caused by immunologically mediated (most often IgE-dependent) 
inflammation after the exposure of the nasal mucous membranes to offending allergens. 
Symptoms of allergic rhinitis include rhinorrhea, nasal obstruction or blockage, nasal 
itching, sneezing, and postnasal drip that reverse spontaneously or after treatment. 
Allergic conjunctivitis often accompanies allergic rhinitis.”11 
 
1.2.1.3 Eczema 
Diagnostic criteria of eczema were defined by Hanifin and Rajka in 1980
12
. The 
definition has been further developed by the United Kingdom Working Party criteria 
and can be used when a skin condition likely is eczema: Itchy skin condition in the last 
12 months plus at least three of, involvement of skin creases, personal history of 
asthma/rhinitis, generally dry skin, onset before two years of age and flexural 
dermatitis
13
.  
 
1.2.1.4 Anaphylaxis 
A position paper for anaphylaxis in children has been prepared by the EAACI 
Taskforce on Anaphylaxis in Children, defining anaphylaxis as a “severe, life-
threatening generalized or systemic hypersensitivity reaction”. The clinical criteria are: 
acute onset, two or more organ systems involved (skin-mucosa/ respiratory tract/ 
cardiovascular system/ gastrointestional tract) or hypotension after exposure to known 
allergen
8, 9, 14
. 
 
1.2.2 Prevalence and natural course of allergy 
Allergic disease in the population worldwide has increased dramatically over the last 
decades, but seems to level off in the Western world
15-17
. There are large worldwide 
geographical differences in prevalence of asthma (3%-38%), rhinoconjunctivitis (2%-
24%) and eczema (2%-22%)
16
. 
Allergic symptoms often show a progression throughout childhood from food 
hypersensitivity and eczema in early childhood to inhalant allergy with asthma and 
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increasing prevalence of rhinoconjunctivitis in school age. This process is often 
referred to as “the atopic march”18, 19. The natural course of sensitization follows the 
same route: sensitization to food items in early childhood followed by increasing 
prevalence of sensitization to inhalant allergens from preschool age and onwards
20, 21
.  
In Sweden, the prevalence of sensitization to any inhalant or food allergen increases 
with age from 18%-24% in preschool age
22, 23
 to 20%-25% among young 
schoolchildren
24, 25
. The prevalence of allergic disease in the Swedish paediatric 
population is about 6%-8% for asthma
24, 26
, 5%-17% for rhinoconjunctivitis (increasing 
with age)
24, 25, 27
, 11%-23% for eczema
25, 26
 and 2%-8% for doctor diagnosed (14%-
24% for self-reported) food allergy
28-30
.  
 
1.2.3 Adverse food reactions, food allergy and peanut allergy 
According to the 2010 US National Institutes of Allergy and Infectious Diseases 
(NIAID)-sponsored guidelines, food allergy is defined as an “adverse health effect 
arising from a specific immune response that occurs reproducibly on exposure to a 
given food”31, which means that all adverse reactions from foods are not food allergies. 
Classification of adverse food reactions are illustrated in figure 3. Except food allergic 
reactions, food items may cause health effects in different ways: food poisoning with 
staphylococcus aureus endotoxin is one example of toxic reaction to food
32
. Lactose 
intolerance is a non-immunologic deficiency of lactase and lead to gastrointestinal 
symptoms due to undigested lactose
33
. Celiac disease is an immunologic, but non-
allergic autoimmune disease, with intolerance to food items containing gluten from 
mainly wheat
34
. There are also food allergies, which are not IgE mediated, for example 
contact dermatitis and food protein-induced enterocolitis syndrome (FPIES) with 
typical symptoms of vomiting, diarrhea and hypotension usually within two hours after 
ingestion of the food
35
. However, this thesis focuses on IgE-mediated food allergy only 
and in particular peanut allergy. 
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Figure 3. Classification of adverse food reactions (adapted from Burks
35
) 
 
Clinical peanut allergy has been reported in 0.2%-1.8% of children and has increased in 
westernized countries during the last decades
36-40
. The prevalence of peanut 
sensitization is about 3%-6%
40-42
. Reactions to peanut may be severe
43-45
, are usually 
not outgrown
46-48
 and has a negative impact on quality of life
49, 50
. In many countries 
peanut sensitized children, irrespective if they have experienced allergic symptoms to 
peanut at ingestion
41, 42, 51
, have been advised to avoid peanuts. 
 
1.2.4 IgE cross reactivity between pollens and food items 
“Panallergens” is a term used for families of proteins that have similar function and 
molecular structure and are present in many different types of plants in nature
52
. Cross-
reactivity of IgE between members of these families are common, due to their structural 
similarities. Important plant protein families are the Pathogenesis-related (PR) proteins 
including the Bet v 1 related proteins, the profilins, the prolamin superfamily with lipid 
transfer proteins (LTP) and 2S albumin and the cupin superfamily with 7/8S and 11S 
globulins. In order to belong to the same plant protein family the proteins have to be 
homologous in amino acid sequence or very similar in their biological function and 
structure
53
. All characterized allergens are listed by the World Health Organization and 
International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature 
Sub-committee in a database established in 1984 based on the Linnean system 
(www.allergen.org).  
 
Oral Allergy Syndrome, or pollen-food allergy syndrome, is since decades a well-
known type of food allergy
54
. Typically, a pollen allergic individual experiences 
symptoms from the oral cavity when ingesting certain raw fruits or vegetables. This 
phenomenon is experienced by a majority of pollen allergic individuals. Now we know 
Non-toxic
Immunologisk Non-immunologic
• Lactose intolerance
Allergic Non-allergic
• Celiac disease
IgE-mediated
• E.g. peanut allergy, 
milk protein allergy, 
egg allergy
Non-IgE-mediated
• Rare, children most affected (e.g. ”FPIES”)
• Contact dermatitis
Toxic
• ”food poisoning” –
toxine produced by 
bacteria
• ”Histamine poisoning” 
– tuna, mackerel
Adverse food reaction
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that symptoms from the oral cavity often is caused by cross-reactivity of pollen IgE to 
homologous determinants of the symptom eliciting food
53, 55, 56
. However, some 
individuals exhibit local symptoms from the oral cavity as the first sign of a subsequent 
systemic reaction
57, 58
. This fact has made the definition of OAS difficult. There is a 
need for better diagnostic methods to differ between harmless cross-reactions and 
potentially severe allergy. 
 
1.3 DIAGNOSTIC METHODS FOR FOOD ALLERGY IN GENERAL AND 
PEANUT ALLERGY IN PARTICULAR 
1.3.1 Serum IgE analysis and skin prick testing 
During the last decade the field of diagnosing food allergy has developed rapidly. Skin 
Prick Testing (SPT) was introduced in 1942 and is still widely used
59, 60
. In daily 
clinical work, SPT is used more or less as a “yes or no answer”; to confirm if there is an 
IgE response to the allergen or not. However, wheal diameter at SPT correlates with the 
likelihood of clinical allergy
61-65
 but the SPT results are sensible for variation due to 
circumstances at testing, such as age and skin reactivity
65
, but also batch age and skill 
of the person performing the test . The first commercial serum IgE test, the radio-
allergosorbent test (RAST), was introduced in 1972
5, 66
. It utilized solid phase allergens 
incubated with patient’s sera. Bound IgE was detected with a radio-isotopically labeled 
anti-IgE reagent and radioactivity was measured with a gamma counter. High counts on 
the gamma counter were proportional to high levels of IgE
5, 66
. The technique 
developed further into quantitative IgE results by using enzyme labelling and not 
radioactivity. However, the basic chemistry is the same. Today, there are a couple of 
companies performing IgE assays, for example Immulite by Siemens Healthcare 
Diagnostics and ImmunoCAP by Thermo Fisher Scientific (formerly Phadia AB). The 
ImmunoCAP test is a “sandwich immunoassay”; the allergen of interest is bound to a 
cellulose capsule and reacts with specific IgE in the sample serum. After washing, 
reacting IgE molecules are detected by adding enzyme labelled anti-IgE. 
 
1.3.2 Quantitative IgE 
In 2001, Sampson et al established threshold specific allergen IgE-levels indicating a 
95% likelihood of a clinical reaction to the major food allergens egg, milk, peanut, fish, 
soy and wheat
67
. Probability curves for likelihood of reaction in relation to specific IgE 
levels were plotted. The study subjects were paediatric patients attending the Mount 
Sinai Hospital and were therefore highly selected. The 95% decision point for peanut 
extract IgE was set to 15 kUA/L
67
. Since the test is based on crude peanut extract it did 
not differentiate between sensitization to clinically relevant or harmless allergen 
components in peanut. Other studies have used similar probability curves to predict 
allergy
68, 69
. 
 
1.3.3 Molecular allergology 
1.3.3.1 Molecular allergology in general 
The allergen nomenclature is based on the Linnean system (e.g. peanut is named 
Arachis hypogaea) as mentioned. Plant-derived allergens, are named with the three first 
letters in the genus of the allergen source (e.g. “Ara”) followed by the first letter(s) in 
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the species (e.g. “h”) and an arabic number indicating the chronology of allergen 
discovery (e.g. “1”). 
In 1948 reactions in the mouth and lips were described among patients with rhinitis 
during spring time
70
 and in 1977 an association was shown between birch pollen 
sensitized patients and positive skin test to for example apple and carrot
71
.  
In 1991, Ebner et al identified cross-reactivity of the major birch pollen allergen Bet v 1 
and with similar protein structures on the apple proteins, explaining a large proportion 
of OAS in birch-allergic individuals when eating apple. The following decades, the 
field of molecular allergology advanced and many plant-derived food allergens were 
molecularly and chemically classified
55
. Two different forms of food allergy were 
distinguished: one form where the sensitization process to an allergen (stable to gastric 
digestion) started in the gastrointestinal tract and a second form where prior inhalant 
allergen sensitization caused cross-reaction to food allergen components, i.e. the food 
allergy provoking proteins. Another route of sensitization through the skin has also 
been discussed
72, 73
.  
The pathogenesis-related (PR) proteins are often involved in cross-reactions between 
pollen and plant-derived food. There are several types classified in 17 families; birch 
pollen Bet v 1 and peanut Ara h 8 belong to the PR-10 family. The expression in plants 
is induced by stress factors such as infection, freezing, wounding or senescence of the 
plant. They have antimicrobial and toxic effects. They are also present constitutively in 
many plants and are thought to have other essential functions in plant life except from a 
defence function
74
. 
Profilins constitute another panallergen protein superfamily. Like PR proteins, profilins 
are often causing cross-reactivity between pollen and plant food IgE. Peanut profilin is 
named Ara h 5. Profilins are actin-binding proteins present in most eukaryotic cells and 
are important for the cell cytoskeleton. They were first described as allergens in pollens 
1991 and later in many fruits and vegetables
75, 76
. 
Carbohydrate cross-reactive determinants (CCDs) are allergen structures on 
glycoproteins. CCDs are widely distributed in plants and similar structures are also 
found on insect venoms
77
. IgE to CCDs are common in allergic individuals but have 
low biological activity
78
. 
The most important allergens in many plant-derived food items are the storage proteins 
which belong to two super-families (cupins and prolamins). They constitute a large 
proportion of the protein content in many plant foods, in particular in tree nuts, 
legumes, seeds and cereals
79
. They have a compact 3D structure which make them 
stable to heat and digestion
80
. Hence, sensitization through the gastrointestinal route is 
possible. 
In 2007 when this thesis project was initiated, allergen components had so far not been 
used in clinical practice. Although the different routes of sensitization were discussed, 
the clinical impact of sensitization to different food allergen components had just begun 
to be understood.  
 
1.3.3.2 Molecular allergology and peanut allergens 
In 2007, eight peanut allergens were recognized by the (WHO/IUIS) Nomenclature 
Subcommittee. Ara h 1 and Ara h 2 were characterized by Burks et al in 1991-1992
81, 
82
and Ara h 3 was identified a couple of years later
83, 84
. These three major peanut 
allergens are all peanut storage proteins of the Prolamin (Ara h 2, 2S albumin) and 
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Cupin (Ara h 1 7/8S globulin and Ara h 3 11S globulin) super-families. Ara h 4 is 
nearly identical with Ara h 3
85, 86
. Ara h 5, Ara h 6 and Ara h 7 were identified in 
1999
87
. Ara h 5 is a member of the profilins superfamily and Ara h 6 and h 7 (as well as 
already mentioned Ara h 2) are 2S albumins of the Prolamin super-family. In 2004, 
Mittag et al characterized Ara h 8 belonging to the PR-10 proteins of which the major 
birch pollen allergen Bet v 1 is a member
51
. The Ara h 8 protein is 46% identical to 
birch pollen Bet v 1 in amino acid sequence and therefore Ara h 8 IgE is cross-reactive 
with Bet v 1
51
. Mittag and co-workers also found out that Ara h 8 was very unstable to 
gastric digestion and rather unstable to heat. Other researchers have studied the 
allergenecity of Ara h 1 and Ara h 2 and found them highly stable to heat and digestion 
and even described enhanced allergenicity after roasting
88-90
. Profilins like Ara h 5 were 
known as minor allergens of low clinical relevance
56
. However, for example the celery 
profilin (Api g 4)
91
 and the profilin in zucchini
92
 have been shown to elicit clinically 
relevant reactions.  
 
1.3.4 Oral Food Challenges 
According to the EAACI position paper on food challenges a food challenge should be 
performed either to confirm or exclude the diagnosis of food allergy, for scientific 
reasons, for determination of threshold value of the food or for determining the 
allergenicity of a food. Food challenges can be performed as an open oral food 
challenge (OOFC) or as a double-blind placebo controlled food challenge (DBPCFC). 
In each DBPCFC, neither the patient, nor the doctor or nurse know if the challenge is 
performed with the food item or with placebo. DBPCFC is the “gold standard” method. 
An OOFC is often sufficient in children younger than three years, when only objective 
immediate signs are studied or when there is a high probability of a negative outcome
93
. 
At peanut DBPCFC, it is important to hide the peanut taste and texture in order to 
ensure that the challenge is really blind. At the same time, the peanut allergens have to 
be available, i.e. the blinding must not affect the allergen reactivity. Using vehicles with 
high fat content is effective for blinding, but reduces the availability of peanut 
proteins
94
. Recipes for optimizing blinding and allergen availability has been 
developed
95
.  
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2 AIMS 
The overall aim of this thesis was to analyse sensitization patterns over time to inhalant 
allergens and furthermore to analyse birch pollen- and peanut IgE levels and IgE to 
peanut components in relation to peanut allergy symptoms. 
 
 
Paper I: to assess changes in prevalence of IgE and IgE-levels to inhalant allergens 
between four and eight years of age in a large population-based birth cohort (BAMSE). 
 
Paper II: to investigate reported symptoms of peanut allergy in relation to levels of IgE 
antibodies to peanut and birch pollen in a cohort of children (BAMSE) who were 
evaluated at both four and eight years of age.  
 
Paper III: to investigate IgE reactivity to different peanut, birch and grass pollen 
allergen components and CCD, in relation to symptoms to peanut in children from a 
Swedish birth cohort (BAMSE) at eight years of age. 
 
Paper IV: in a case report of a 15-year-old boy to illustrate occurrence of peanut Ara h 
6 sensitization in the absence of Ara h 2 sensitization and reaction to peanut at 
exposure. 
 
Paper V: to investigate the risk of systemic reactions at oral challenge with peanuts 
among children sensitized to peanut component Ara h 8, but not to Ara h 1-3.  
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3 MATERIALS AND METHODS 
3.1 STUDY DESIGN AND STUDY POPULATION 
The first three papers of this thesis are based on the birth cohort BAMSE. Paper IV is a 
case report of a patient at Sachs’ Children’s Hospital, Södersjukhuset, Stockholm. The 
fifth paper combines study subjects both from the BAMSE cohort and from Sachs’ 
Children’s Hospital. 
 
3.1.1 BAMSE birth cohort 
BAMSE is a prospective longitudinal population based birth cohort of 4 089 children
96
. 
The abbreviation “BAMSE” stands for “Children, Allergy, Milieu, Stockholm, 
Epidemiological Study” (Barn, Allergi, Miljö i Stockholm, en Epidemiologisk studie). 
The main original aim of the BAMSE study was to establish risk factors for the 
development of allergy related diseases in childhood up to the age of four.  
Through Child Health Care Centers (barnavårdscentraler), attended by 99.8% of all 
new born infants the first year of life
97
, inclusion of two months old children born 
between February 11 1994 and November 22 1996 were made. Inclusion was to be 
closed when a calculated number of 4 000 children was reached. Target population was 
all children born in certain areas of central and North-Western Stockholm, chosen to be 
representative of the Stockholm area with suburbs, Figure 4. 
 
 
 
Figure 4. Recruitment areas, BAMSE birth cohort, 1994-1996. 
 
During the recruitment period 7 221 children were born in the specified areas. Of these, 
477 (6.6%) could never be reached and another 1 256 (17.4%) were excluded due to the 
exclusion criteria: plan to move within 1 year, not Swedish speaking, seriously ill child, 
older sister or brother already included in the study. Of the remaining eligible 5 488 
children 4 089 (75%) completed the first questionnaire when the child was about two 
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months of age and infants enrolled at this time point were defined as the study 
population, Figure 5.  
 
 
Figure 5.Study design and included study subjects in the five papers of this thesis. 
 
Posted parental questionnaires on parental allergy, lifestyle factors, socio-economic 
status and environmental factors were completed when the child was two months old 
(baseline questionnaire). When the child was 1, 2, 4 and 8 years the parents answered 
questions mainly on the child’s symptoms of allergy related diseases. In the cohort of 
4 089 children, response rate at each follow up was 96%, 94%, 91% and 84%, 
respectively. At four and eight years of age all children with completed questionnaires 
at the current follow up were invited for a clinical examination including blood 
sampling. From these examinations, sera was available in 2 614 (64%) and 2 461(60%) 
of the 4 089 children at four and eight years of age, respectively. Later follow ups at 12 
and 16 years of age (on-going) were not included in this thesis and will not be 
discussed further, Figure 6. 
 
7221 children born in the recruitment 
areas
6744
5488 eligible
The study population
The parents of 4089 (75%) children 
answered the first questionnaire when 
the median age of the child was 2 
months
Study I
Complete data 
concerning IgE at 4 
and 8 years of age.
N=2033
Study II
Complete relevant 
answers to Q4 and Q8 
and IgE data on peanut 
and birch at 4 and 8 
years of age.
N=1928
Study III
200 randomly collected 
children:
50 sensitized to peanut
50 sensitized to peanut 
and birch
50 sensitized to birch
50 not sensitized to 
peanut or birch
N=200
Study IV
Case report, patient 
from Sachs’ Children’s 
Hospital.
Study V
Complete data 
concerning IgE to 
Peanut and birch at 8 
years of age. 
Sensitization to peanut 
component Ara h 8 and 
not to Ara h 1-3.
N=62
Study V
Patients from Sachs’ 
Children’s Hospital. 
Sensitization to peanut 
component Ara h 8 and 
not to Ara h 1-3.
N=98
477 (6.6%) children could not be contacted
1256 (17.4%) children were actively excluded
1399 (25.5%) of the families declined to participate or 
never answered
BAMSE 
cohort
Sachs’ 
Children’s 
Hospital
237 patients referred to Sachs’ childrens’ 
Hospital and blood-tested for nut allergy
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Figure 6. Timeline of the BAMSE study follow-ups 1994-2012.  
 
Non-responders and actively excluded families (N=1 418) were contacted in 1996 with 
a two pages questionnaire on key exposures (parental smoking, keeping of pets and 
allergic heredity). Response rates were 58% and 83%, respectively. Parental allergy or 
keeping of pets did not differ, but parental smoking was significantly higher in the non-
responder-excluded group as compared to the families included in the BAMSE study 
(maternal and paternal smoking 18% maternal and 23% paternal smoking in non-
responders vs 9% maternal and 17% paternal smoking in included families)
96
. 
 
Study I included only children from which blood was obtained at both four and eight 
years of age (N=2 033).  
  
Study II included children where data on symptoms to peanut and IgE antibody levels 
to birch and peanut at both four and eight years of age were available (N=1 928). 
 
Study III had a nested study design: among the 2 480 children from whom blood was 
drawn at 8 years of age, 200 children representing four different patterns of 
sensitization to peanut and birch pollen were randomly selected: group A consisted of 
50 of 52 children sensitized to peanut, but not to birch pollen; group B consisted of 50 
of 141 children sensitized to both peanut and birch pollen; group C consisted of 50 of 
237 children sensitized to birch pollen but not to peanut. Finally, group D consisted of 
50 of 2012 children with sensitization neither to peanut nor to birch pollen. 
 
Study IV was a case study and did not involve the BAMSE cohort. 
 
Study V included 160 children recruited both from the 8 year follow up of the BAMSE 
cohort (n=62) as well as patients from Sachs’ Children’s Hospital (n=98) based on 
sensitization to peanut allergen components, see 3.2.1.2.  
 
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
1 year symptom 
questionnaire
N=3925 (96%)
2 year symptom 
questionnaire
N=3843 (94%)
4 year follow up
questionnaire: 3720 (91%)
Dust: 3610 (88%)
PEF: 2966 (73%)
Blood: 2614 (64%)
8 year follow up
questionnaire: 3431 (84%)
Spirometry: 2613 (64%)
Blood: 2461 (60%)
11-14 year
follow up
questionnaire
N=3371(82%)
16 year follow up
On-going!
Questionnaire,
Spirometry, Blood, 
etc. About 75% 
response rate 
expected
Baseline (2 months): 
Exposure 
questionnaire and 
dust 
N=4089(100%)
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3.1.2 Study subjects recruited from the Sachs’ Children’s Hospital 
The allergy unit at Sachs’ Children’s Hospital is one of two hospital based allergy units 
in the Stockholm County with an outpatient clinic managing referrals of allergic 
children and providing specialized health care for children with moderate to severe 
allergy related diseases. 
 
Paper IV is a case report of a 15-year-old boy who was referred from the allergy unit of 
Sachs’ Children’s Hospital to the Day Ward at the same hospital for an oral peanut 
challenge. 
 
Paper V: From 2007 until 2010 a clinical database of 237consecutive children, 
attending the outpatient allergy clinic at Sachs’ Children’s Hospital with suspected 
peanut or tree nut allergy, was established. Of the 237 children 192 children had IgE 
≥0.35 kUA/L to peanut extract and 98 of these children were included based on their 
sensitization pattern to peanut allergen components (see 3.2.1.2).  
 
3.2 METHODS 
3.2.1 Sensitization 
3.2.1.1 Inhalant and food allergen sensitization 
The blood samples from clinical examinations at four (N=2 614) and eight (N=2 461) 
years of age in the BAMSE cohort were screened with Phadiatop
®
 [a mixture of 
common inhalant allergens: birch, timothy, mugwort, cat, dog, horse, mould 
(Cladosporium herbarum) and house dust mite (Dermatophagoides pteronyssinus)] and 
fx5
®
 [a mixture of common food allergens: cow’s milk, hen’s egg white, soy bean, 
peanut, cod fish and wheat] (ImmunoCAP
®
, former Phadia now Thermo Fisher 
Scientific, Uppsala, Sweden). Sera with a positive Phadiatop or fx5, defined as IgE 
levels ≥0.35 kUA/L, were analysed for allergen-specific IgE to the airborne and food 
allergens listed above. Levels between 0.35 and 100 kUA/L were registered, and an IgE 
concentration ≥100 kUA/L was in the statistical evaluation given the value of 101 
kUA/L. Three percent of the analyses for allergen-specific IgE failed due to too scarce 
amount of blood. The analyses were performed by a certified laboratory (the Clinical 
Immunology and Allergy Unit, Department of Medicine, Karolinska Institutet and 
Karolinska University Hospital, Stockholm).  
 
Sensitization was defined as presence of IgE to the allergen tested at a level of ≥0.35 
kUA/L 
 
3.2.1.2 Peanut allergen component sensitization 
In Study III, IV and V, IgE to peanut allergen components in sera was analysed. During 
the timeframe of the studies the laboratory technique on allergen specific IgE 
developed with availability of peanut allergen components for IgE testing. This is the 
reason why different laboratory procedures were used in the different studies. 
 
Microarray: In Paper III IgE to components from peanut (native Ara h 1, h 2, h 3, 
recombinant Ara h 8), birch pollen (recombinant Bet v 1, Bet v 2), timothy pollen 
(native Phl p 4, native Phl p 1, 5, 12) and peach (recombinant Pru p 3) as well as 
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carbohydrate cross-reactive determinant (CCD) were measured using an experimental 
in-house microarray developed and run by Phadia AB, Uppsala, Sweden. The purified 
allergen components were spotted on nitrocellulose membranes on microscope glasses. 
30 µl sample serum was added and incubated. After washing, bound IgE antibodies 
were detected with fluorescent anti-IgE and fluorescence intensity was measured at 
wavelength 635 nm
98
. Individual cut-off levels were established for each allergen, 
based on background fluorescence from negative samples, and ranges between 400 and 
600 FU. 
 
ImmunoCAP
®
: In paper IV and V the common ImmunoCAP test (description, see 
1.3.1) was used to analyse IgE to allergens of peanut protein components, birch pollen, 
Bet v 1 and CCD. At the time of inclusion of patients in study V, the peanut allergen 
components Ara h 1, h 2, h 3, h 8 and h 9 were commercially available (recombinant 
extracts). At the time for challenge of the patients in paper IV and V the 2 S albumin 
Ara h 6 (sequence Acc. No. Q647G9) was available in a limited amount at former 
Phadia AB, Uppsala. Recombinant Ara h 6 was produced in Escherichia coli as a 
hexahistidine-tagged recombinant protein using a synthetic gene construct and purified 
by immobilized metal ion affinity chromatography followed by ion exchange 
chromatography, as described
99
. Experimental ImmunoCAP Ara h 6 tests were 
prepared
100
. 
 
Of the 2 480 children from the BAMSE cohort with blood samples at eight years of 
age, 195 were sensitized to whole peanut extract i.e. peanut IgE≥0.35 kU/L. All these 
children were further analysed with ImmunoCAP in November 2009 for IgE to 
available peanut allergen components and 62 of these were sensitized to Ara h 8 but not 
to Ara h 1, h 2 or h 3 and included (Ara h 8 IgE≥0.35 kU/L and Ara h 1-3 
IgE<0.35kU/L) in study V. 
 
In blood samples from the 237 children from Sachs’ Children’s Hospital peanut 
components Ara h 1-3 and Ara h 8 were analysed (ImmunoCAP) in clinical routine. 98 
patients were sensitized to Ara h 8, but not to Ara h 1, h 2 or h 3 and were therefore 
included in study V. 
 
3.2.2 Study subject characteristics 
3.2.2.1 Questionnaires  
Paper I-III: In the BAMSE study we used answers from parental questionnaires on 
parental allergy, lifestyle and environmental factors when the child was two months old 
(baseline questionnaire). Data from the questionnaires at one, four and eight years were 
also used, in which the parents answered questions on symptoms of the child’s allergic 
diseases, medications and breast-feeding. In the questionnaires for four and eight years 
of age, specific symptoms on reactions to peanut and birch pollen were asked for as 
well as active avoidance of peanut.  
 
Paper IV-V: Parents of included children from Sachs’ Children’s Hospital in study V 
received questions by posted mail concerning current peanut consumption similar to the 
questions used in the 8 year of age BAMSE questionnaire. Those who did not answer 
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via returning posted mail or email were asked the same questions via telephone calls by 
physician or nurse.  
 
3.2.2.2 Medical records (Paper IV-V) 
In Paper IV, the case report, details of clinical history and laboratory details were 
retrieved from the patient’s medical records at Sachs’ Children’s Hospital. 
 
In Study V, a history of systemic reaction at peanut exposure was retrieved from 
medical records when present and was also used for evaluation of reaction severity. 
Furthermore, data on doctor’s diagnosis of asthma, allergic rhinitis/rhinoconjunctivitis, 
eczema and food allergy, other than allergy to peanut, were also retrieved from the 
same medical records. The International Classification of Disease, tenth revision (ICD-
10) was used.  
 
3.2.2.3 Clinical investigations (Paper I-V) 
Paper I-III and V: At four and eight years, all families with completed questionnaires in 
the BAMSE cohort were invited to a clinical examination including pulmonary 
function tests and blood sampling. At four and eight years, 2 614 (70%) and 2 461 
(72%), respectively, of the invited families participated in a clinical examination 
(including blood sampling). The examination was performed at the Department of 
Occupational and Environmental Health, Stockholm County Council, by paediatric 
nurses. 
 
Paper IV-V: All children who underwent oral peanut challenge at Sachs’ Children’s 
Hospital were interviewed and examined by a physician before challenge. Heart- and 
lung-auscultation and inspection of oral cavity were performed and blood pressure was 
measured before challenge and at challenge if symptoms occurred.  
 
3.2.3 Oral peanut challenges (Paper IV-V) 
Paper IV: The patient in the case report took part in a pre-study in order to evaluate a 
three dosing steps procedure at open oral challenge (0.1 + 1 + 10 g of roasted peanuts at 
20 minutes interval). This was done in patients where no reactions were expected.  
 
Paper V: Oral challenge was performed in children without current peanut 
consumption. 
Inclusion criteria for oral challenge: Children with current sensitization to Ara h 8 but 
not to Ara h 1, h 2 or h 3 and with no previous exposure to peanuts, avoidance of 
peanuts for different reasons or anaphylaxis grade I or milder after previous exposure to 
peanuts.  
Exclusion criteria for oral challenge: Children with anaphylaxis grade II-III after 
previous exposure to peanuts
8
. Children with on-going allergic reaction to other food 
and inhalant allergens were also excluded. 
Peanut tolerance: Children with reported peanut consumption at least at one occasion 
in the last 12 months without symptoms or discomfort. 
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3.2.3.1 OOFC (Open Oral Food Challenge), paper V 
An open oral food challenge (OOFC) was performed in four stages: 100 mg, 1 g, 5 g 
and an additional 5 g of pure roasted peanut with 20-minutes intervals, total amount 
11.1 grams of peanut equivalent to 13-15 peanuts, followed by one hour observation 
period after the final dose. Before the challenge, an intravenous catheter was 
administered on all children, under local anaesthesia (EMLA
®
) when wanted. 
 
3.2.3.2 DBPCFC (Double Blind Placebo Controlled Food Challenge) 
In cases of a non-systemic or systemic reaction up to anaphylaxis grade I at OOFC or a 
previous documented systemic reaction up to anaphylaxis grade I at peanut exposure, a 
DBPCFC was performed
95, 101
. Double-blind, placebo-controlled food challenge was 
performed by an experienced nurse using a challenge medium (chocolate brownie like 
cookie) containing 11% peanut and 7% fat in increasing doses every 30 min in five 
steps from 1 mg to 5 g peanut
95
, followed by a 2-hour observation period after the final 
dose. The code for un-blinding was kept sealed for the study object, nurse and doctor 
until both challenges (active and placebo) were completed. 
 
3.2.4 Definition of outcomes 
3.2.4.1 Paper I 
The first study had a descriptive approach and main outcomes were sensitization to 
different allergens at four and/or eight years of age. Definition of sensitization, see 
paragraph 3.2.1.1 above. 
 
When the study group of BAMSE children in this thesis was compared with the 
children of the BAMSE study base (the original cohort) information on asthma, rhinitis, 
eczema, exclusive breastfeeding, parental smoking, cat ownership and parental allergy 
was used. The comparison was done in order to determinate if there were differences in 
background factors between the study group and the entire cohort. Definitions were 
based on questionnaire answers at 2 months (Q0), one year (Q1), four years (Q4) and 
eight years (Q8) as follows:  
Asthma: Q4 and Q8, respectively; Parental report of at least 4 episodes of wheeze in the 
last 12 months or at least one episode of wheeze during the same period, combined 
with prescription of inhaled steroids
102
. 
Rhinitis: Q4 and Q8, respectively; Fulfilling the ISAAC definition of rhinitis – parental 
report of prolonged rhinitis (sneezing or a runny or blocked nose) without common 
cold the last 12 months prior to questionnaire
16
. 
Eczema: Q4 and Q8, respectively; Parental report of dry skin in combination with itchy 
rash for two weeks or more AND typical localization (face or arms/legs flexures or 
wrists/ankles or neck) in the last 12 months prior questionnaire AND/OR doctor’s 
diagnose of eczema since previous questionnaire
102
. 
Exclusive breastfeeding: Exclusively breast fed 4 months or more (Q1)
103
. 
Parental Smoking: Any of the parents smoked at least one cigarette per day at the time 
of Q0
104
. 
Cat ownership: Had a cat at home at the time of Q0
104
. 
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Parental allergy: Mother AND/OR father with doctor’s diagnose of asthma and asthma 
medication AND/OR doctor’s diagnose of hay fever in combination with furred pets- 
and/or pollen-allergy at the time of questionnaire Q0
105
. 
 
3.2.4.2 Paper II 
Main outcomes were symptoms to peanut at four and eight years of age, respectively. 
Secondary outcomes were symptoms to birch at four and eight years of age, 
respectively. 
 
Questionnaire data, at four and eight years of age and obtained prior to blood-sampling 
were used. Symptoms to peanut and birch were defined as a positive answer to any of 
the following questions in the four or eight year of age questionnaires:  
Symptoms to peanut at four years: ‘After two years of age, has your child at any 
occasion experienced any problems from eating peanuts such as vomiting, diarrhea, 
eczema, urticaria/itching rash, swollen lips/eyes, itchy, blocked or runny nose or 
asthma?’ 
Symptoms to peanut at eight years: ‘Is your child allergic to peanuts’. If yes, symptom 
options were ‘nose/eye symptoms’, ‘mouth-itching’, ‘breathing difficulties’, 
‘vomiting/diarrhea’, ‘eczema’, ‘urticaria’ or ‘excluded because of early symptoms’. 
Peanut had to be indicated for at least one of these symptoms.  
Symptoms to birch at four years: ‘Has your child at any occasion after two years of age 
experienced problems with wheeze, cough, itching skin rash, sneezing, runny or 
blocked nose or red itchy eyes when trees are leafing (month of May)?’ 
Symptoms to birch at eight years: ‘Has your child experienced wheeze or disturbing 
cough, itching eczema or sneezing, runny or blocked nose or red itchy eyes related to 
birch pollen?’ 
 
As in paper I, background factors and current allergy related disease (sex, parental 
allergy, asthma, eczema, rhinitis, inhalant allergen IgE levels) in the study population 
(N=1 928) were compared with the same data of children in the original cohort at two 
months and eight years of age. The same definitions were used as in paper I (see 
3.2.4.1). 
 
3.2.4.3 Paper III 
Main outcome was reported symptoms to peanuts at eight years of age as a 
dichotomous outcome. Secondary outcome was type of symptom(s) to peanut or peanut 
tolerance. 
 
Peanut-symptomatic children 
Positive answer was required to the following question in the eight-year-questionnaire 
regarding the latest 12-month period: ‘Is your child allergic to any food item?’ 
Symptom options were ‘nose/eyes symptoms’, ‘mouth-itching’, ‘breathing problems’, 
‘vomiting/diarrhea’, ‘eczema’, ‘urticaria’. Reactions to peanut had to be indicated on at 
least one of these symptoms or reported as ‘excluded from the diet during the last 12 
months because of previous symptoms’. Symptoms from nose/eyes or oral cavity were 
considered as mild symptoms, whereas wheeze or dyspnoea were considered as severe 
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symptoms
14
. Gastrointestinal symptoms, eczema and urticaria were not possible to 
classify according to severity from questionnaires. 
 
Peanut-tolerant children 
Children with none of the symptoms mentioned above in relation to peanut 
consumption and reported by the parents during the latest 12 months prior to Q8. 
 
As in paper I, background factors and current allergy related disease (sex, parental 
allergy, asthma, eczema, rhinitis, inhalant allergen IgE levels) in the study population 
(N=200) were compared with the same factors of all children participating in the eight 
years of age follow up. The same definitions were used as in paper I. 
 
3.2.4.4 Paper IV 
The described anaphylaxis was graded according to a modified definition of the 
EAACI position paper on anaphylaxis in childhood
8, 14
. Two or more organ systems 
needed to be involved in the reaction. Severity score (grade I-III) was based on the 
organ system most affected. 
 
3.2.4.5 Paper V 
Main outcome in the peanut challenge study was outcome at oral peanut challenge. 
 
Peanut tolerance: Children with reported peanut consumption at least at one occasion in 
the last 12 months without symptoms or discomfort (not challenged). This could be 
confirmed of all children recruited from Sachs’ Children’s Hospital and thus they were 
regarded as tolerant (n=31). The 47 peanut tolerant children included from the BAMSE 
cohort (definition see outcomes, Paper III) were not contacted further for logistic 
reasons, they were considered tolerant at the time of inclusion in paper V (eight years 
of age). 
 
Outcomes of the oral food challenge: 
Negative outcome:  
- No objective symptoms during 60 minutes after last dose of peanut at oral 
provocation and no parental report of late symptoms 24 h after challenge. 
- Oral allergy syndrome (OAS), i.e. local symptoms from the oral cavity - itching 
and tingling of the lips, mouth, and throat but without skin symptoms, breathing 
difficulties or tissue swelling
60
. 
Positive outcome: 
- Systemic reaction with manifestations from the cerebrovascular system, gastro-
intestinal tract, lower respiratory tract or skin. For classification of a reaction as 
anaphylaxis, symptoms were required to be present from the cerebrovascular 
system or at least two of the following organ systems: gastro-intestinal tract, 
upper or lower respiratory tract or skin. Severity score was based on the organ 
system most affected
8, 14
. 
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3.3 STATISTICAL ANALYSES 
In Paper I-III the included children were compared to the BAMSE study base (the 
entire cohort) with respect to background factors at inclusion (sex, parental allergy, 
parental smoking and cat ownership) and at follow-up at four and eight years of age 
(asthma, rhinitis, eczema, IgE-levels to inhalant and food allergens). Dichotomous 
variables were tabulated on proportions and 95% Confidence Intervals (95% CI) were 
calculated. Intervals that did not overlap were considered as statistically different. 
Continuous variables (IgE-levels) had a skewed log distribution and were subject to a 
logarithmic transformation before group comparisons with Student’s t-test. 
 
Paper I-III and V used the following statistical measures and analyses: Prevalence was 
expressed in total numbers and percentages. 95% CI were calculated when appropriate 
and intervals that did not overlap were considered as statistically different. Chi-square 
test was used for statistical comparisons of dichotomous variables. Fisher’s exact test 
was used if one comparison group consisted of 5 observations or less. Allergen-specific 
IgE levels were log normally distributed and subject to a logarithmic transformation 
before analysis. Student’s t-test was used (on the logarithmic scale) for analysis of the 
continuous IgE-variables. Mean IgE levels were presented as geometric mean (and 
95% CI) in Paper I-III and as median (and range) values in Paper V.  
 
Statistical analyses specific for the different papers: 
In Paper I, Multiple logistic regression models were used for calculations of odds ratios 
(ORs) and 95% CI between specific sensitizing allergen at 4 years in relation to 
sensitization at 8 years
106
. Adjustments in the multivariate analyses were made for 
parental allergy and sex, which affected the risk of sensitization to the outcome 
allergens tested with 10% or more. Because allergic children are more likely to be 
sensitized to multiple allergens, adjustments were made for each inhalant and food 
allergen tested at 4 years. 
 
In Paper II, the relationship between symptoms to peanut and IgE antibody levels was 
estimated using a logistic regression model. The odds ratios (ORs) were estimated 
using logistic regression models and 95% CI were generated. Fitted predicted 
probability curves according to the levels of the specific IgE to peanut were plotted 
using the results from the logistic regression. All tests were according to Wald
106
. 
Logistic regression was also used to investigate peanut symptoms in relation to 
sensitization to birch and timothy. Several models for identifying confounders were 
run. Among others, variables of heredity, sex and exposure to tobacco smoke were 
tested, but since they did not confound the results by 10% or more, they were not 
included in the analyses.  
 
In Paper III Spearman’s rank correlation test was used to establish the strength of 
relationship between specific IgE antibody responses in the microarray. 
 
Paper IV did not contain any statistical analyses. 
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Paper V did not contain any statistical method specific for this study (see above, second 
paragraph). 
 
In all studies, p-values <0.05 were considered significant. All statistical analyses were 
performed with STATA Statistical Software (release 9 and 11; StataCorp, College 
Station, Texas, USA). 
 
3.4 ETHICAL PERMISSIONS 
Ethical permissions for all studies were received from the regional ethics review board 
at Karolinska Institutet, Stockholm, Sweden. Register numbers for permissions were:  
Study I: 93-189, 98-175, 02-420 
Study II: 93-189, 98-175, 02-420 
Study III: 93-189, 98-175, 02-420 
Study IV: 2012/99-32 
Study V: 93-189, 98-175, 02-420, 2010/1331-31/3, 2012/99-32 
 
Informed consents were obtained from the parents, and in some cases also the child, in 
all families participating in the studies. 
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4 RESULTS 
In Paper I-III, background data of children selected in the three studies were compared 
to the same data of children in the BAMSE study base in order to investigate if any 
selection bias existed in the study groups. Children in the study groups did not differ 
significantly in sex, parental allergy or prevalence of asthma, eczema, rhinitis or in 
levels of specific IgE (assessed using Phadiatop
 
and fx5) at four or eight years of age 
compared to remaining children in corresponding age group or in important 
background factors of the study base in any of the studies (data not shown). 
 
4.1 SENSITIZATION TO INHALANT ALLERGENS BETWEEN FOUR AND 
EIGHT YEARS OF AGE (PAPER I) 
At four years 309 (15%) and eight years 510 (25%) of the 2 033 children were 
sensitized to at least one inhalant allergen (p<0.001). The prevalence of positive (IgE 
≥0.35 kU/L) tests and the IgE concentrations, presented as geometric mean, of the 
selected inhalant allergens in relation to age are presented in Figure 7. The prevalence 
increased significantly with age for all allergens. Both at four and eight years, birch 
pollen followed by pollen of timothy, cat and dog dander were the most common 
sensitizing allergens.  
 
   
Figure 7. Prevalence of sensitization (IgE≥0,35 kUA/L) and geometric mean values in kUA/L to 
specific airborne allergens at four and eight years of age in 2 033 identical children. 
§ p-values for difference in group IgE levels at eight years as compared to four years of age. 
* p<0.01 difference in prevalence at eight years as compared to at four years of age. Asarnoj et 
al, Clin Exp Allergy. 2008 Sep;38(9):1507-13 
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Sensitization at four years of age to common inhalant allergens was persistent in most 
children at eight years of age (Table 1). This was true for 97% of the children sensitized 
to pollen of birch, 86% to timothy, 97% to mugwort, 94% to dander of cat, 91% to dog 
and 94% to horse at four years of age. Among these children all the allergen-specific 
IgE-levels increased significantly (p<0.01) except for IgE levels of mould and mite 
allergen. Among children with remittent sensitization, i.e. sensitization at four, but not 
at eight years, only 38% of the children were mono-sensitized and as many as 20% of 
the children were sensitized to 4 inhalant allergens or more. The allergen-specific levels 
of all 48 children who remitted ranged from 0.35 to 3.92 kUA/L, geometric mean 0.75 
kUA/L. 
 
Table 1. IgE antibody levels (geometric mean) to inhalant allergens among children sensitized 
at four or eight years only or sensitized both at four and eight years.†. Asarnoj et al, Clin Exp 
Allergy. 2008 Sep;38(9):1507-13  
 
 At 4 but not at 8 
years 
in 48 children 
Both at 4 and 8 years 
in 279 children 
At 8 but not at 4 
years 
in 426 children 
   IgE   IgE at 4 ɸ IgE at 8 
§ 
  IgE 
Allergen N % g.mean 
(kUA/L) 
 
N % g.mean 
(kUA/L) 
 
g.mean 
(kUA/L) 
 
N % g.mean 
(kUA/L) 
 
Birch 5 0.3 0.9 181 8.9 6.5*** 21.3*** 119 5.9 3.4 
Timothy 16 0.8 0.8 101 5.0 2.2*** 10.0*** 178 8.8 2.6 
Mugwort 1 0.1 0.5 31 1.5 1.2*** 3.3*** 104 5.1 1.3 
Cat 7 0.3 0.7 111 5.5 3.3*** 8.1*** 142 7.0 2.6 
Dog 8 0.4 0.6 85 4.2 2.2*** 5.0*** 144 7.1 1.1 
Horse 4 0.2 0.7 58 3 2.9** 5.1*** 71 3.5 1.5 
Mites 11 0.5 0.9 25 1.2 1.4 NS 1.9 NS 56 2.8 1.4 
Mould 6 0.3 0.7 12 0.6 2.2 NS 2.2 NS 23 1.1 1.0 
† Internal missing: 0.9%-2.2% (of 2033 children) for each allergen tested. 
§ For all allergens, except mould and mites, the IgE antibody levels were significantly higher 
among those with persistent sensitization compared to those with late onset sensitization.  
ɸ For all allergens, except mould and mites, the IgE antibody levels increased significantly 
between 4 and 8 years among those with persistent sensitization. 
p<0.01,  p<0.001, NS= Not significant.  
 
 
Among eight-year-old children we analysed the association between specific IgE levels 
(kUA/L) to the pollens and furred animals and the number of allergens (pollen and/or 
animal species) that the child was sensitized to. With increasing number of sensitizing 
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pollens, the IgE levels to each of birch and timothy pollen increased. This pattern was 
also seen for sensitization to furred pets.  
 
We further analysed sensitization to inhalant and food allergens at four years of age and 
the odd ration for persistent or onset of sensitization to the 4 most common inhalant 
allergens (birch, timothy, cat and dog) at eight years of age. A multiple logistic 
regression model adjusting for identified confounders such as sex and parental allergy, 
but also for all allergens tested, was used. The odds ratios decreased after adjustment 
for the other allergens which was most pronounced for IgE to mould spores, mugwort 
pollen and horse dander, but comparably less for birch pollen and fx5. Sensitization to 
any pollen among the four-year-olds increased the odds for sensitization to birch and 
timothy at eight years. Furthermore, sensitization to birch pollen increased the odds 
ratios significantly for sensitization to both cat and dog at eight years.  
 
4.2 REPORTED SYMPTOMS TO PEANUT BETWEEN FOUR AND EIGHT 
YEARS AMONG CHILDREN SENSITIZED TO PEANUT AND BIRCH 
POLLEN (PAPER II) 
At four years, 106 (5.5%) of the children were sensitized to peanut and 181 (9.4%) 
were sensitized to birch. At eight years the corresponding proportions were 142 (7.4%) 
and 293 (15.2%), Figure 8. From four and eight years the proportion of children 
sensitized to peanut, but not birch (subgroup 1), remained essentially unchanged, 2.2% 
and 1.9% at the two respective ages, whereas the proportion of children sensitized to 
both peanut and birch pollen (subgroup 2) seemed to increase over the same period 
(3.3% and 5.4%, respectively, p=0.002), Figure 8.  
 
 
Figure 8. Changes in sensitization to peanut and birch pollen between four and eight years of 
age among 1 928 children living in Stockholm. Asarnoj et al, Allergy 2010 Feb; 65(2): 213–9. 
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At four years 2.9% (n=56) of the 1 928 children reported symptoms to peanut and at 
eight years the corresponding proportion was 5.7% (n=109).The prevalence of 
sensitization to peanut in combination with reported symptoms to peanut was 1.8% 
(n=34) at four years and 3.9% (n=76) at eight years of age.  
At four years of age the proportion of children reporting symptoms from peanut did not 
differ among peanut sensitized children with or without concomitant sensitization to 
birch pollen (subgroup 2 vs subgroup 1); 34% vs 29% (p=0.53). However, at eight 
years of age 76% of the children who were sensitized to peanut but not to birch pollen 
(subgroup 1) reported symptoms to peanut, whereas among children sensitized both to 
peanut and birch pollen (subgroup 2) only 46% reported such symptoms, p=0.002. All 
types of peanut-related symptoms at eight years of age (see definition of symptoms 
3.2.4.2), except eczema, were reported more frequently among children in subgroup 1 
than in subgroup 2, Figure 9. Significant differences were seen for breathing 
difficulties; 27% vs 10%, p=0.008 and urticaria; 16% vs 6%, p=0.048). However, 19 
peanut and birch pollen sensitized children reported systemic reactions. 
 
 
Figure 9. Proportion of different symptoms from peanut among 142 eight-year-olds sensitized to 
peanut but not to birch or peanut and birch. Figures above bars represent the absolute 
numbers of children. *p<0.05. 
 
 
It is noteworthy that children de novo-sensitized to peanut between four and eight years 
(n=52) were mostly asymptomatic (85%) to peanut and concomitantly sensitized to 
birch pollen (87%). 
 
At four years of age, although the difference was not statistically significant, the mean 
IgE level to peanut was higher among children sensitized to peanut and not birch pollen 
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(subgroup 1) than among children sensitized to both peanut and birch pollen (subgroup 
2), 8.2 kUA/L (95% CI 4.5-14.9) and 4.5 kUA/L (2.9-6.9), respectively, p=0.093. 
However, at eight years this difference in IgE antibody concentrations was significant: 
12.0 kUA/L (6.1-23.9) and 4.3 kUA/L (3.1-6.0), respectively, p=0.003).  
 
Sensitization to timothy did not independently influence on peanut symptoms (data not 
shown). 
 
When the children were four years of age, 13 of them had not yet been exposed to 
peanuts. Exclusion of these 13 children from the analysis did not change the results. 
 
4.3 IGE TO PEANUT ALLERGEN COMPONENTS: RELATION TO 
PEANUT SYMPTOMS AND POLLEN SENSITIZATION IN 8-YEAR-
OLDS (PAPER III) 
4.3.1.1 Component sensitization within the four groups 
The four groups (A- sensitized to peanut, B - sensitized to birch and peanut, C - 
sensitized to birch and D - not sensitized to peanut or birch) differed substantially 
regarding the IgE reactivity to Ara h 1, 2, 3 and 8, CCD and profilin (Bet v 2/Phl p 12) 
with the use of microarray technique, Figure 10. IgE reactivity to Ara h 1, 2 and 3 was 
most common in group A. No individual had IgE reactivity to Ara h 1 or Ara h 3 
without an associated Ara h 2 sensitization. No child in group A had IgE reactivity to 
Ara h 8. IgE reactivity to the peanut storage proteins (Ara h 1, 2 and 3) was present 
only in children sensitized to peanut (group A and B), whereas 11 children in group C 
(birch pollen sensitized only) had IgE reactivity to Ara h 8. IgE antibodies to Ara h 8 
were common in children sensitized to birch pollen (group B and C; 38% and 22%, 
respectively). The prevalence of IgE reactivity to CCD was low in all groups, ranging 
from 0 to 18%, and was most prevalent in group B. Similarly, none of the children in 
group A and B had IgE antibodies to LTP, i.e. Pru p 3 (peach LTP used as a crude 
marker of Ara h 9).  
 
When the IgE level to peanut extract was investigated in relation to individual IgE 
reactivity to the peanut allergen components, children with reactivity to Ara h 1, 2 or 3, 
but not to Ara h 8, had significantly higher IgE antibody level (geometric mean, 95% 
CI) to peanut extract (18.9 kUA/L , 11.5-31.0 kUA/L, n=46) than children with 
reactivity to Ara h 8 only (1.0 kUA/L, 0.60-1.7 kUA/L, n=23). 
 
Of the 100 peanut-sensitized children (group A and B), 25 were to our surprise IgE 
negative to all tested peanut components in the microarray including CCD and profilin 
(Fig. 10). In 17 of these 25 children, the peanut-specific IgE levels were below 1 
kUA/L. Seven of the negative children had responses to one or more peanut-related 
components in the microarray just below cut-off (data not shown).  
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Figure 10. IgE reactivity pattern to individual peanut allergens, Bet v 1, profilin and cross-
reactive carbohydrate determinant (CCD) measured in a microarray-based assay. 
Group A; children sensitized to peanut and birch pollen, group B; children sensitized to peanut 
but not birch pollen, group C; children sensitized to birch pollen but not peanut, group D; 
children sensitized neither to peanut nor to birch pollen. The intensity of the IgE antibody 
binding is indicated as light grey (medium/low binding, >400-600 FU depending on allergen) 
and dark grey squares (high binding, >5000 FU). Subjects with self-reported peanut allergy are 
marked with a black square in the symptom column. NA, information not available. Asarnoj et 
al, Allergy 2010; 65: 1189–1195. 
 
 
4.3.1.2 Reported symptoms to peanut within the four groups and in relation to 
peanut allergen components 
Symptoms to peanut were more common in peanut-sensitized children without 
concomitant birch pollen sensitization (group A: 74%, 95% CI 60%-85%) than in 
children sensitized to both peanut and birch pollen: (group B: 43%, 95% CI 29%-58%) 
Figure 10.  
 
IgE reactivity to Ara h 2 was found in 73% of the children with reported allergic 
symptoms to peanut. Only seven of the peanut tolerant children (5%) had IgE 
antibodies to Ara h 2, all but one with low/moderate IgE reactivity (<5000 FU)(Figure 
10). 
Symptoms to peanut were reported among the 46 children (group A and B) with IgE 
reactivity to Ara h 1, 2 or 3 but not Ara h 8 and the 23 children in group B and C with 
IgE reactivity to Ara h 8 only and not to Ara h 1, 2 or 3 (Figure 11). Eighty-seven 
percent of those with Ara h 1, 2 or 3 IgE reactivity reported any symptom to peanut, 
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whereas only 18% of those with IgE reactivity to Ara h 8 reported such symptoms 
(P<0.001). The differences were significant only for any symptoms as well as upper 
and lower respiratory symptoms, possibly due to the limited number of children (Figure 
11). Interestingly, sensitization to Ara h 1 or Ara h 3 in addition to Ara h 2 as compared 
to children sensitized to Ara h 2 only was associated with several symptoms (97% vs 
70%) and more respiratory symptoms (50% vs 9%) (p=0.016 and p=0.002, 
respectively). 
 
 
Figure 11. Parental reported symptoms to peanut during the last 12 months among children 
sensitized either to at least one of Ara h 1, h 2 or h 3 (n=46, black bars) or to Ara h 8 but not to 
Ara h 1, h 2 or h 3 (n=23, grey bars). Asarnoj et al, Allergy 2010; 65: 1189–1195. 
 
 
IgE reactivity to profilin (Bet v 2 and Phl p 12), the major grass allergen components 
(Phl p 1, 4 and 5), grass extract or CCD was not associated with reported symptoms to 
peanut (data not shown). 
 
4.4 PEANUT COMPONENT ARA H 8 SENSITIZATION AND TOLERANCE 
TO PEANUT (PAPER IV-V) 
Paper IV reports a case of anaphylaxis grade II in a 15 year old boy. 
This patient was allergic to pollen and furred pets with symptoms of rhino-
conjunctivitis, a doctor diagnosed asthma and atopic eczema. Following a positive 
allergy test before school age, he has refrained from consumption of tree nuts and 
peanuts. He had no history of anaphylaxis. He was IgE-tested nine months prior to 
challenge and fulfilled our inclusion criteria for the pre-study, i.e. exhibited IgE 
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antibody levels to Ara h 1, Ara h 2 and Ara h 3 < 0.35 kUA/L and to Ara h 8 > 0.35 
kUA/L.  
At the open challenge, he exhibited oral itch, stomach pain, vomiting, diarrhea and 
developed a lower respiratory obstruction, but without reduction in SaO2 (99%). He 
became increasingly anxious, fatigue and restless. Blood pressure and heart rate were 
stable and normal. He was given oral antihistamine, adrenaline i.m., intravenous fluid, 
betametason i.v. and salbutamol inhalation. He was hospitalized and recovered in a 
couple of hours.  
IgE testing of a blood sample taken at the time of challenge showed a doubling of IgE 
antibody concentration to peanut as compared to a sample drawn 9 months earlier. In 
addition, barely detectable levels of IgE antibody to Ara h 2 and Ara h 9 were noted, 
however, not at all accounting for the rise in IgE to the peanut allergen extract. Analysis 
of IgE to Ara h 6 in a blood sample drawn two months after the peanut challenge 
revealed a clear sensitization to Ara h 6 (24 kUA/L), despite a very modest level of IgE 
to Ara h 2 (0.12 kUA/L). 
 
A flowchart of the 160 included children and challenges in paper V is illustrated in 
Figure 12. Eighty-two children were peanut consumers and were not invited for 
challenge. Sixty two children were invited for challenge among which 44 had never 
tasted peanuts, 12 had previously experienced reactions to peanut and 6 had eaten 
peanuts earlier in life without symptoms, but had been advised to avoid peanuts 
because of previous allergy test results. No children with anaphylaxis gr II-III after 
exposure to peanuts were found. It is noteworthy that the children who ate peanuts and 
were therefore not challenged, did not exhibit lower IgE levels to peanut or to Ara h 8 
than the group of challenged children; rather the contrary (median peanut IgE among 
challenged/ not challenged was 1.3 vs 1.6 kUA/L and corresponding Ara h 8 IgE among 
challenged/ not challenged was 9.4 vs 14 kUA/L, and with no statistically significant 
differences).  
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Figure 12. Flow chart of 160 children, recruited from two different sources, initially sensitized 
to Ara h 8 ≥0.35 kU/L but not to Ara h 1, Ara h 2 and Ara h3 <0.35 kU/L, of whom 62 
underwent oral challenge. 
 * Urticaria in perioral eczema/ redness in soft palate; ** See Table 2. 
 
 
4.4.1.1 Open oral challenge (OOFC) 
Only 14 OOFC children (23%) reported oral cavity or pharyngeal itch (OAS) after 
challenge, but in only two of these children symptoms could be verified objectively, 
Figure 12. Interestingly, the OAS occurred at the first or second dose, ceased 
spontaneously and did not occur at the following dose steps. There was no association 
between IgE-levels to peanut extract, to Ara h 8 or to birch pollen in relation to OAS 
symptoms. There were no statistically significant differences in age, sex or other 
allergy-related disease between children with and without OAS.  
 
4.4.1.2 DBPCFC 
In two children, DBPCFC with peanut was carried out since they both had had 
suspected systemic reactions/anaphylaxis grade I to peanut previously; one within the 
study and another before the study. One study subject (“subject 1”) was accidently 
challenged during birch pollen season when having symptoms to birch pollen. At 
challenge he reacted with worsening of his conjunctivitis and rhinitis as well as 
subjective breathing difficulties. At re-challenge (DBPCFC), 6 months later and outside 
birch pollen season, he passed the DBPCFC. His IgE to peanut extract and peanut 
components (including Ara h 6 and Ara h 9 <0.35kUA/L) were almost unchanged at 
challenge as compared to time of inclusion. 
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(n=98)
Recruited from the population-based 
BAMSE survey 
(n=62)
Loss to follow-
up, (OAS  at age 8) 
Not possible to 
reach
(2)
Avoiding peanuts/ 
symptoms at exposure at 
age 8 (15)
Consuming peanuts 
during last 12 months. 
Considered tolerant
Not challenged (35)
Avoiding peanuts: 
previous reaction / never 
eaten
(53)
Loss to follow-up/excluded 
(14): 
[Declined/unreachable (12)
Disabled (2)
Previous systemic reaction to 
peanut  (0)]
Oral challenge
(62)
No symptoms (46)
Subjective OAS (12)
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The second study subject (“subject 2”), a nine-year-old boy, had been admitted to an 
emergency room with anaphylaxis grade I after having had snacks containing peanut 
five years prior to our study. He performed a DBPCFC and reacted to the last dose with 
lip swelling, stomach cramping and objective tiredness, Table 2. At the time of the 
challenge, his IgE to peanut extract was 8.8 kUA/L, but nine months prior to challenge 
his IgE to peanut extract had been 1.5 kUA/L. All peanut components were unchanged, 
Table 2. 
 
Table 2. Characteristics, IgE levels and symptoms of a 9-year-old boy (“subject 2”) who 
underwent DBPCFC due to a previous suspected anaphylaxis grade I. 
Challenge DBPCFC 
Sex/age yrs Boy/9 
Sachs’ 
patient/BAMSE 
Sachs 
Tasted peanut Yes 
 f13 
 
 
Ara  
h 1 
 
 
Ara  
h 2 
 
 
Ara  
h 3 
 
 
Ara  
h 6 
 
Ara  
h 8 
Ara  
h 9 
Peanut sIgE prior 
inclusion 
<0.35 <0.35 <0.35 <0.35 n.d. 1.7 n.d. 
Peanut sIgE 9 
months prior 
challenge 
1.5 <0.35 <0.35 <0.35 0.45 14 <0.35 
Peanut sIgE at re 
analysis 1 month 
prior challenge 
8.8 <0.35 <0.35 <0.35 0.45 14 n.d. 
Symptoms at 
previous exposure 
Age 4 years. Oral tingling, unilateral conjunctival swelling, 
stomach pain, tiredness 
Symptoms at 
challenge 
Lip swelling, stomach cramping, tiredness 
 
4.4.1.3 IgE to peanut allergen components at challenge 
 
No blood was drawn from three children at challenge, all of them without symptoms at 
challenge. Serum from 59 (95%) of the challenged children was re-analysed for IgE to 
peanut and birch pollen extracts as well as to peanut components. All children still 
exhibited IgE to Ara h 1, h 2 or h 3 <0.35 kUA/L, despite the fact that 9.7 months had 
passed in average between identification and challenge. Two children had Ara h 6-IgE 
>0.35 kUA/L: one child had IgE to Ara h 6 of 0.73 kUA/L and passed the challenge. 
Another child with IgE to Ara h 6 of 0.45 kUA/L failed (Table 2) and developed a 
systemic reaction (see above). In none of the patients neither CCD- nor Ara h 9 (LTP) 
IgE levels were associated with any symptoms at challenge (data not shown). 
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4.5 ADDITIONAL RESULTS 
4.5.1 Comparison of component analyses results: Microarray and 
ImmunoCAP 
In November 2009, all available sera (n=185) of peanut sensitized children of the 
BAMSE cohort (n=195) from the eight year follow-up were analysed for IgE to peanut 
allergen components Ara h 1, h 2, h 3, h 8 and h 9 (lipid transfer protein) which at this 
time all was commercially available. The ImmunoCAP method was used. 
Comparison of these results with component IgE results from the experimental 
microarray, performed in 100 of the 195 sera in December 2007, is presented in Figure 
13.  
 
 
Figure 13. Modified Figure 10, paper III, page 26. Detection of IgE with the ImmunoCAP 
method of children sensitized to peanut extract, but negative to peanut allergen components by 
using the microarray technique (red and pink). 
 
Sixty-six of the 100 sera analysed with both methods showed corresponding results. 
Nineteen sera negative (<600 FU) in the microarray assay for Ara h 8 were positive 
with the ImmunoCAP for Ara h 8. The median ImmunoCAP Ara h 8 IgE was 4.7 
kUA/L (range 0.52-46) among those initially negative for Ara h 8 with the microarray 
as compared to 33 kUA/L (range 8.9-99) among the microarray positive samples. The 
peanut LTP component Ara h 9 was not analysed with the microarray. Instead, a peanut 
LTP proxy, the peach LTP (Pru p 3) was used and was negative in all 100 peanut-
positive samples. When the ImmunoCAP method was used, five sera (5%) showed IgE 
to Ara h 9 (range 0.36-1.0 kUA/L), three of these children reported peanut symptoms or 
peanut exclusion, no systemic symptoms were indicated. Taking the results from both 
ImmunoCAP and the experimental microarray together, IgE to peanut allergen 
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1091 3669 5080 5760
1432 4591 5196 5845
1585 4770 5498 5969
3295 4937 5725 6386
4222 5154 6062 6442
4257 5426 6354 6514
4297 5526 6783 6797
4992 6252 7058 6835
5840 6420 7093 6928
6041 7200 7103 7009
Group A
peanut
Group B
Peanut & birch
Group C
birch
Group D
Ara h9
Ara h9
Ara h9
Ara h9
Ara h9
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components could still not be detected in 13 (one missing sample in ImmunoCAP) of 
the 100 originally peanut extract sensitized children (as compared to 25 sera of peanut 
sensitized children but without reactivity to to peanut components when using the 
microarray). Thus, some peanut allergen components seem to be lacking. However, 
median peanut IgE level among in the 13 sera was low; 0.58 kUA/L (range 0.36-3.3 
kUA/L). Three of these children reported symptoms at exposure to peanut, but in none 
of the children the symptoms were systemic. 
 
Of the 185 peanut extract sensitized children (>0.35 kUA/L), peanut component 
allergen IgE analyses with ImmunoCAP showed that in 32 (17%) children, IgE to Ara 
h 1, h 2, h 3, h 8 and h 9 was below 0.35 kUA/L. Among these children median IgE to 
peanut extract was 0.8 (range 0.41-5.4) kUA/L. Seven of them reported any symptom to 
peanut or exclusion of peanuts, no report of systemic symptoms except one who 
reported eczema after peanut exposure. Of the 32 children, 15 had IgE to at least one of 
the tested peanut allergen components between 0.1 and 0.34 kUA/L or IgE to 
CCD/profilin in the microarray. For the remaining 17, no detectable IgE to any 
commercially available peanut allergen component was found, indicating that all 
peanut allergen components are not available for IgE testing. However, 13 of these 17 
children were peanut tolerant. The other four did not indicate any systemic reactions. 
 
4.5.2 Children with reported systemic reactions to peanut in Paper III 
sensitized to Ara h 8 only 
In study III, two eight year olds sensitized to Ara h 8 and not to Ara h 1-h 3 reported 
systemic reaction to peanut at exposure (breathing difficulties and urticaria, 
respectively). Both of them were included in study V and had an oral peanut challenge 
performed about seven years after the eight years of age follow up. They both passed 
the challenge without any symptoms, not even having symptoms of OAS, Figure 14. At 
retesting before the challenge the children had the same sensitization profile with IgE 
only to Ara h 8 and not to Ara h 1, h 2 or h 3.  
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Figure 14. Modified Figure 11, paper III, page 27. Parental reported symptoms to peanut during 
the last 12 months among children sensitized either to at least one of Ara h 1, 2 or 3 (n=46, 
black bars) or to Ara h 8 (n=23, grey bars) at eight years of age. The children reporting 
systemic reactions to peanut were seven years later orally challenged with peanut (study V) 
without any symptoms. 
 
4.5.3 IgE Immunoblotting (Paper V) 
The boy with anaphylaxis grade I in paper V had unchanged IgE levels to known 
peanut components despite increasing levels of IgE to peanut extract (1.5 to 8.8 
kUA/L). Thermo Fisher Scientific helped us to perform an immunoblot (or Western 
blot) on the boy’s serum outside the study. Peanut proteins were first separated 
according to size by gel electrophoresis and then transferred horizontally to a flat 
membrane where the proteins were available for detection by IgE antibodies present in 
the boy’s serum. The immunoblotting showed intense IgE binding to one protein band 
at 35 and faint binding to a double band at about 70 kDa, but no binding to smaller 
protein molecules (Ara h 2, h 6, h 8-9 ). The IgE binding proteins observed in the 
immunoblot analysis did not share epitopes with rAra h 1 or rAra h 3 and are of 
unknown identity.  
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5 DISCUSSION  
 
5.1 THE SENSITIZATION PROCESS OVER TIME 
Our results of the prevalence of sensitization on inhalant allergens at four (15%) and 
eight (25%) years of age in paper I are in line with other studies
107-110
. For reasons of 
exposures, allergen patterns of sensitization will be different in different regions around 
the world. For example among trees, birch pollen sensitization dominates in Northern 
Europe, whereas sensitization to hazel pollen dominates in Central/Western Europe and 
olive pollen sensitization in the Mediterranean countries
111, 112
. The sensitization 
prevalence to house dust mites (HDM) was low in our study (1.8 % and 4.1% at four 
and eight years of age, respectively) as compared to others. For example Kjaer 
Formsgaard et al reported 7.4% sensitized among six year-olds in their population 
based birth cohort (“DARC”) from Odense Denmark21. This difference in sensitization 
rate to mites between the DARC and the BAMSE study is probably due to low 
exposure to HDM in the Stockholm area
113, 114
.  
Several studies have been designed to describe the natural course of sensitization to 
common inhalant allergens in the population
21, 107, 115, 116
. For all studies a dynamic 
process of allergic sensitization seem to be common over time. Grass sensitization is 
the dominant sensitizing allergen among inhalants across Europe in contrast to birch 
sensitization which dominated in our study. As for the other allergens tested for in our 
study, similarities in sensitization patterns were seen with other studies: the prevalence 
of sensitization to inhalant allergens increases during childhood whereas reduction in 
IgE levels below detection level to inhalant allergens occurs rarely and when present 
this is mostly found when IgE-levels were low at previous follow up
115, 116
. 
Between four and eight years of age, occurrence of specific IgE to the most common 
inhalant allergens almost doubled in our cohort. The relative increase in the proportion 
of sensitized children was larger for timothy and dog as compared to birch and cat. 
Both timothy and dog sensitization seemed to catch up in prevalence and was rather 
similar compared to prevalence of sensitization to birch pollen and cat dander at eight 
years of age. To our knowledge this has not been described before. To our surprise, 
birch pollen sensitization at eight years of age was strongly associated with 
sensitization to peanut at eight years of age (OR 24.2) and peanut sensitization at eight 
years of age was more common as compared to other similar population based 
studies
40, 41
. In paper I, the association between sensitization to birch pollen and peanut 
was not mentioned since we did not have any fair explanation and since the finding 
could be more of by chance character at the time for this study. However, since these 
results were rather intriguing a decision was taken to go into depth with our data, since 
we also became aware of the paper by Mittag et al on Bet v 1 and Ara h 8 cross 
reactions, which actually resulted in the remaining part of this thesis
51
. 
 
5.2 FROM SPT AND IGE OF ALLERGEN EXTRACTS TO CRD 
In late 2006/early 2007, at the start of studies II and III, the field of CRD in clinical care 
was still quite unknown and not in use. The best available tool for allergy diagnostic 
purposes was quantification of SPT or serum IgE results in order to predict the 
likelihood of a clinically relevant allergy
42, 61, 65, 67, 117
. Since more than half a century it 
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has been known that allergic rhinitis during springtime is associated with oral cavity 
symptoms to some fruits and tree nuts
70, 71
. Cross-reactions between pollens and food 
items is common and causes oral allergy syndrome (OAS)
60
. Such cross-reactions were 
actually clinically described for birch pollen and peanut already 1982
54
 and at a 
molecular level in 2004-2005
51, 118
. However, in review articles on food allergens or 
OAS at the study start such cross reactions were either not mentioned or considered as 
representing “true” peanut allergy and not only OAS due to cross reactions between 
birch pollen and peanut
79, 118, 119
.  
 
In Paper II, we could for the first time demonstrate that there was a significant 
difference in frequency of reported peanut symptoms in eight year olds sensitized to A) 
both to peanut and birch pollen or B) to peanut, but not to birch pollen (40% and 76% 
report of symptoms, respectively, p= 0.002). Furthermore, we could show that 
symptoms to peanut in the former group (peanut and birch pollen sensitized) were 
milder than in the latter group (only peanut sensitized). The most plausible reason for 
this was the cross-reactivity between allergens in birch pollen and peanut, since peanut 
allergen extract contains Ara h 8, a PR-10 allergen, which is homologous to the major 
birch pollen Bet v 1. Possibly, Ara h 5 which is a profilin and therefore homologous to 
the birch pollen profilin Bet v 2 may have played a role as well in this context. Both 
Ara h 8 and Ara h 5 have been characterized by others
51, 87
. Other studies on 
sensitization to peanut and other pollens (grass) have also been found to be in line with 
our findings of peanut tolerance in peanut and birch pollen co-sensitized individuals
41
. 
Furthermore, there are studies which describe similar associations between birch pollen 
and other food items, e.g. allergens of hazelnut and birch pollen
54, 71, 120
. 
 
In paper II we found that IgE levels to peanut were lower in the “peanut-and-birch” 
group, compared to the “peanut only” group (geometric mean 4.3 kUA/L and 12 kUA/L, 
respectively, p=0.0032). Low IgE to peanut in a population based sample may reflect 
cross-reactivity to other allergens of plant origin, in particular that of pollen. In cases of 
“true” peanut allergy, higher IgE levels to peanut are usually seen67. However, this may 
partially be age dependent, i.e. very young children with anaphylaxis to peanut may 
still have low IgE to peanut (personal communication Magnus Wickman and Caroline 
Nilsson).  
 
In Paper III we wanted to further examine the relationship between cross sensitization 
between pollen and peanuts. The presence of relevant allergen components explaining 
the differences in symptoms between the sensitization groups described in Paper II was 
investigated. In 2007, 200 blood samples, representing four different sensitization 
patterns regarding peanut and birch pollen, were analysed in an experimental 
microarray
121
. We found that 83% of those with IgE reactivity to the peanut component 
Ara h 2 also reported allergic symptoms to peanut, compared to children exclusively 
sensitized to Ara h 8 where peanut symptoms were reported in 18% only. These results 
are in line with other studies, showing the importance of Ara h 2 IgE in peanut 
allergy
122-125
 . In addition, the symptoms in the latter group of 23 Ara h 8 sensitized 
children were milder, although two children reported symptoms likely of systemic 
origin (lower respiratory symptoms and urticaria, Figures 11 and 14) which is discussed 
further below in 5.4.  
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Since the participating children in Paper II and III were not challenged, we were not 
able to draw very firm conclusions of the clinical relevance of Ara h 8 sensitization. 
Therefore, we decided to perform a study in order to evaluate the risk of systemic 
reactions for individuals with isolated Ara h 8 sensitization (Paper V). At the time for 
preparation of this study, we learned that IgE to the 2S albumin Ara h 6 may occur even 
in the absence of IgE to Ara h 2, another 2S albumin, and most likely causing a severe 
reaction to peanut (Paper IV, case report). Isolated Ara h 6 sensitization should be rare 
since the two 2S albumins Ara h 2 and Ara h 6 are homologues
87, 126
. As a result of this 
finding, we decided to perform extended analysis of peanut IgE, including also Ara h 6 
in study V. 
 
143 (99.3%) of the 144 children evaluated in study V were tolerant to peanut or 
exhibited mild OAS, mainly with subjective symptoms from the oral cavity that 
disappeared spontaneously during the challenge procedure. One boy had a DBPCFC 
because of a suspected systemic reaction at an open challenge during birch pollen 
season and with symptoms of rhino-conjunctivitis at challenge. However, apart from 
pollen season he passed a DBPCFC to peanut. This boy’s first challenge during pollen 
season failed, which indicates there is an elevated risk of peanut reaction at challenge 
for individuals with on-going allergic symptoms. This is also in accordance with the 
observation in a recent paper from our group where we could show that anaphylaxis to 
foods is more common during pollen season among pollen allergic individuals
127
.  
The only boy who had a suspected systematic reaction within the study had a previous 
history of possible systemic reaction as well as a slightly elevated Ara h 6 IgE (0.45 
kUA/L). Immunoblot analysis revealed that an unknown protein of about 35 kDa 
accounted for most of the binding of peanut-reactive IgE. We believe it is more likely 
that the symptomatic reaction occurred as a result of sensitization to this protein of 
unknown identity than to Ara h 6 IgE, which only accounted for a small proportion 
(0.45 kUA/L) of the IgE response to peanut extract (8.8 kUA/L).  
  
5.3 PEANUT ALLERGENS 
The diagnostic utility of molecular allergology or component resolved diagnostics 
(CRD)
128
 has developed rapidly since this thesis project started in 2006. Below is a 
summary of gained knowledge from 2006 to date (2012) with respect to peanut 
allergens and allergenicity in relation to results from our studies. A list of officially 
recognized peanut allergens is established by International Union of Immunological 
Societies (IUIS) Nomenclature Subcommittee and available at www.allergen.org. 
Eleven different peanut allergen components named Ara h 1 through Ara h 11 are 
identified in total by April 2012. 
 
5.3.1 Peanut allergen components in relation to our results 
5.3.1.1 Ara h 8  
Birch pollen Bet v 1 homologous components (members of the PR-10 protein family) 
are present in many plant derived foods, for example Ara h 8 in peanut, Gly m 4 in 
soy
129, 130
, Cor a 1 in hazelnut
131, 132
 and Mal d 1 in apple
133, 134
. PR-10 mediated 
reactions to these foods seem to differ quite considerably in frequency and severity. 
Severe reactions derived from Ara h 8 or Mal d 1 have to our knowledge not been 
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described so far, whereas systemic reactions to soy are documented in patients with 
isolated Gly m 4 sensitization
129, 135, 136
. Significant reactions in patients with Cor a 1 
sensitization without sensitization to hazelnut storage proteins or LTP (Cor a 8) have 
been described in a minority of patients, but there are too few studies to draw firm 
conclusions on Cor a 1 and risk of systemic reactions
131
. The Ara h 8 protein is present 
in very low amount in peanuts and is known to have low stability to gastric digestion 
and heat 
51
. This is likely the explanation of our findings of symptoms only from the 
oral cavity among those with isolated Ara h 8 sensitization. The low stability also 
suggests that Ara h 8 sensitization is primarily driven by birch pollen cross-reactivity 
and not through passage of the gastrointestinal tract. Possibly, roasting of peanuts partly 
destroys the Ara h 8 protein molecule which explains the low proportion of children 
who react at exposure to commercially available peanuts which are roasted in our part 
of the world. However, if a larger amount of peanuts would be ingested rather rapidly, 
and Ara h 8 only become partly degraded, a systemic reaction may theoretically occur 
in analogy with described reactions from the soy protein Gly m 4
135, 136
 Mittag et al 
characterized Ara h 8 in 2004 and performed oral challenges in peanut sensitized 
individuals, sensitized to not only Ara h 8, but also to Ara h 1-3. In their paper they 
suggest that severe reactions caused by Ara h 8 may occur
51
. However, it is evident 
from their paper that all the six patients with isolated Ara h 8 sensitization reacted only 
with OAS at challenge, except one patient who also exhibited dermal flush.  
 
5.3.1.2 Ara h 1, h 2, h 3 and h 6 
The 2S albumin peanut component Ara h 2 sensitization was in Paper III the most 
important marker of genuine peanut allergy, as in several other studies
37, 122-125, 137
. The 
Ara h 2 protein is stable to heating and gastric digestion
138-143
. In our study the strong 
association to peanut symptoms was found in particular in children with Ara h 2 
sensitization in combination with sensitization to Ara h 1 and/or Ara h 3. IgE binding to 
increasing number of peanut allergens has shown to be associated with more severe 
reactions to peanut
144
. Alternatively, concomitant sensitization to Ara h 2 and Ara h 1/h 
3 may solely be a consequence of high IgE levels to Ara h 2; IgE levels to Ara h 1 and 
Ara h 3 generally are lower than to Ara h 2
101
 and could both be below detection limit 
in patients with low IgE reactivity to Ara h 2. High IgE-levels to Ara h 2 are associated 
with increased risk of peanut allergic symptoms
37, 101
. Quantitative IgE levels were not 
available in Paper III since the microarray method is only semi-quantitative. However, 
all children with strong IgE response to Ara h 2 in the microarray (>5000 FU) were 
also sensitized to Ara h 1 and/or Ara h 3, Figure 10. Ara h 1 and Ara h 3 sensitization 
per se are of less diagnostic value for peanut allergy compared to Ara h 2
123, 124
 and in 
our study Ara h 1 and Ara h 3 IgE were only found in combination with Ara h 2 
sensitization. 
The Ara h 2 homologue 2S albumin Ara h 6
87
 has recently been found to be a relevant 
peanut allergen. Like Ara h 2 it has high stability to digestion and heat as well as high 
degranulation capacity in vitro 
138-143, 145
. Ara h 2 and Ara h 6 are extensively cross-
reactive and Ara h 6 IgE is thought to be found only in Ara h 2 sensitized individuals
87, 
137, 146
. However, in Paper IV, we concluded that Ara h 6 sensitization may occur even 
in the absence of Ara h 2 sensitization and also may cause a severe reaction to peanut at 
exposure. 
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5.3.1.3 Other peanut allergens: Ara h 5(profilin), Ara h 9 (LTP) and CCD 
Peanut profilin Ara h 5, homologous with birch Bet v 2 profilin, is considered as a 
minor peanut allergen, and may serve as a marker of any profilin sensitization from 
different plant sources
75
. In Paper III, Ara h 5 was not measured since it was not 
available. Instead Ara h 5 was represented by birch profilin Bet v 2 and timothy profilin 
Phl p 12. Such IgE reactivity was seen in six of the 100 peanut sensitized children, all 
six were also birch sensitized and none of them reported systemic symptoms to peanut.  
Peanut LTP Ara h 9 was identified by Krause et al in 2009
147
. LTP proteins are known 
to be highly stable to digestion and heating
148, 149
. Ara h 9 is an important and clinically 
relevant peanut allergen in the Mediterranean area, but likely not in Central and 
Northern Europe where sensitization is rare
123, 150, 151
. Our findings in Paper III are in 
line with these geographical differences: in the 100 peanut sensitized Swedish children, 
the microarray method did not recognize any LTP-sensitized individual (Pru p 3) 
although the additional ImmunoCAP analysis identified species specific IgE to Ara h 9 
(>0.35 kUA/L) in five children. Three of them reported exclusion of peanuts from diet 
or local symptoms to peanut and there was no association to systemic reactions. In 
Paper V, Ara h 9 was determined in 59 children who were peanut challenged. Only two 
of these children were tested positive (>0.35 kUA/L) for Ara h 9 IgE; one of them (Ara 
h 9 IgE 4.1 kUA/L) reported oral cavity symptoms of the initial doses at the oral 
challenge which ceased at the last doses, the other was tolerant (Ara h 9 IgE 8.3 
kUA/L).  
Cross-reactive carbohydrate determinants (CCD) IgE is induced by pollen sensitization 
and considered to contribute to clinically irrelevant peanut sensitization
152
. Our studies 
support that postulation; 11% and 10% of tested children in Paper III and V, 
respectively were CCD sensitized. None of these children had systemic symptoms 
except for one child in Paper III, who also was Ara h 2 sensitized.  
 
5.3.2 Clinical utility of peanut component IgE testing 
There are now numerous studies showing that Ara h 2 IgE provides good accuracy as a 
diagnostic tool for peanut allergy in many areas
37, 122-125
. However, lack of Ara h 2 
sensitization can probably not be used to predict peanut tolerance worldwide, since 
other allergenic molecules, such as Ara h 9, may be of clinical importance in certain 
areas, e.g. Spain
151
. Hence, increasing IgE levels to whole peanut extract without 
increasing component IgE levels of those which are available today should prompt 
caution. Detection of isolated IgE to Ara h 8 in a peanut sensitized individual may 
primarily serve as a valuable pedagogic diagnostic instrument for information of the 
clinical relevancy of peanut sensitization in birch allergic patients.  
 
The problem with sensitization without symptoms or sensitization without previous 
exposure has resulted in considerable anxiety and fear of severe reactions to peanut in 
otherwise rather healthy individuals. Food allergy has shown to have a negative impact 
on quality of life
49, 50, 153
. With the use of CRD, we are now hopefully heading towards 
less restrictive advices on elimination of foods from the diet in a substantial number of 
birch pollen allergic patients. The difficulties to disentangle harmless reactions from 
harmful will hopefully be reduced by using allergen component testing.  
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However, there may be allergen components not yet characterized. Their importance 
from a clinical point of view needs to be shown. In Paper III, we noted that out of 100 
peanut sensitized children (IgE to peanut extract>0.35 kUA/L) we could not pinpoint 
the sensitizing peanut allergen in 25 sera. After re-analysing the samples with more 
sensitive ImmunoCAP, commercially available from autumn 2007 (Magnus Wickman 
personal communication), 13 of these 100 sera were still lacking explanatory 
sensitizing peanut components (one missing sample) and none of these children 
reported systemic reactions to peanut.  
 
5.4 STRENGTHS AND WEAKNESSES OF THE PRESENT 
INVESTIGATIONS 
In the studies including children from the BAMSE cohort (Paper I-III and V), the 
population based design enables us to generalize our findings to the paediatric 
population in corresponding ages, at least in the Stockholm area. The longitudinal 
approach makes it possible to study the sensitization process and development of 
symptoms to peanuts over time in the same individuals. The large number of 
participants and high response rates at all follow ups are unique. The proportion of 
smokers was lower amongst parents in included families as compared to non-
responders initially of the study
96
. Nevertheless, if this lower participation rate among 
smokers would influence the frequency of allergic diseases, it would probably lead to 
underestimations rather than overestimations of disease, since smoking is a known risk 
factor for the development asthma
154-156
.  
 
The ImmunoCAP specific IgE assay is the most commonly used assay for analysis of 
serum levels of IgE antibodies and it is approved by the US Food and Drug 
Administration
4
. The method is standardized. When possible, this assay was used for 
analysing circulating IgE levels in our studies. In Paper III, specific IgE analysis to 
peanut components was not available on ImmunoCAP, instead an experimental 
microarray assay was used. The advantage of this assay was the ability to analyse IgE 
antibodies to a large number of allergen components with a very small volume of 
serum (30µl). The drawback of using the experimental microarray assay was reduced 
performance in sensitivity when it comes to detection of IgE to peanut components, 
especially IgE to Ara h 8, see above 4.5.1. The reason for this may be that the choice of 
cut off-level was set relatively high (600 FU) due to higher fluorescent background 
than for instance for Bet v 1 (cut off level 500 FU). Another speculative explanation 
could be that the fragile protein structure of Ara h 8 may be better preserved when 
coupled to the ImmunoCAP solid phase as compared to when spotted to the 
nitrocellulose membrane used in the microarray assay (personal communication Robert 
Movérare). Nevertheless, when the peanut-IgE positive serum samples from Paper III 
were re-analysed with ImmunoCAP it was obvious that the systematic measurement 
errors in the microarray diluted the results and not the opposite, since most of the 
additionally detected IgE reactivities were to Ara h 8 in asymptomatic individuals 
(Figure 13).  
 
In Paper II and III, data on peanut symptoms were derived from questionnaires and not 
from observed oral food challenges which are considered more objective
35
. Self-
reported symptoms or - as in our studies - parental reported symptoms, are known to be 
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over reported
157
, and hence most probably would dilute the associations of peanut 
tolerance and concomitant birch sensitization/isolated Ara h 8 sensitization. In our 
challenge study (Paper V), we were able partly to evaluate this possibility of over 
reporting. Thus, some children were invited for oral peanut challenge after several 
years had passed since they were identified as possibly Ara h 8 sensitized. The two 
children with isolated Ara h 8 sensitization who reported systemic symptoms from 
peanut in Paper III (Figures 11 and 14) and in the eight years of age questionnaire were 
challenged within the study V at the age of 14 and 17 years, respectively, and were 
found to be peanut tolerant at oral challenge. Of course, we cannot rule out that these 
children had grown out of the clinical peanut allergy even if this is unlikely since the 
IgE levels and pattern of sensitization to peanut was identical. 
 
Since our main aim was to evaluate the risk of systemic peanut reactions in children 
sensitized to Ara h 8, but not Ara h 1, h 2 or h 3 in paper V, we decided that DBPCFC 
was not needed since systemic reactions are very difficult to fake. Instead, we used an 
open oral challenge four step procedure in children without history of severe reactions 
to peanut. This procedure is less time consuming as compared to our standard 
procedure. Our previous challenges in our clinic in children with isolated Ara h 8 
sensitization suggested that there were not many severe reactions to expect. Similar 
methods have also been used by others
37
. However, when setting up the study we 
initially had one patient who reacted on our “fast track” oral challenge and at that time 
with three dosing steps only and with the last dose of 10 g of peanut. Due to this 
reaction we changed the challenge procedure of the study into a four dosing step design 
by splitting the last dose of 10 g into two doses of 5 g 20 minutes apart in order to 
capture severe reactions more rapidly and possibly at a lower dose of peanut.  
 
5.5 CONCLUDING REMARKS AND OUTLOOK 
In our first study we have analysed the natural course of sensitization to inhalant 
allergens between four and eight years of age in a large population based cohort. In 
short time we intend to analyse IgE data from our on-going sixteen-year follow up of 
the same cohort. These data will provide unique opportunities to study the sensitizing 
process in a larger population based sample from pre-school age up to adolescence. 
There are to date few studies on longitudinal data on sensitization
158
. Sensitization to 
peanut components in a longitudinal perspective will also be investigated with the aim 
to describe the natural course of peanut allergen component sensitization. 
 
 
In Papers II-V we have systematically investigated birch pollen IgE and peanut IgE in 
relation to symptoms to peanut including the clinical impact of birch homologous 
peanut component Ara h 8, which seems to indicate peanut tolerance. Ara h 1, h 2 and 
h 3 seems to indicate genuine peanut allergy. In a near future, we plan to examine 
associations of IgE levels of Ara h 1 and h 3 in relation to symptom severity and the 
dependency of IgE to Ara h 1 and h 3 in relation to Ara h 2. Possible, Ara h 1 and h 3 
may only serve as proxies for IgE to Ara h 2. 
 
In Paper III and V we failed to identify the sensitizing allergen components responsive 
for detected IgE in some of the children with sensitization to peanut extract. In paper 
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III, components explaining the IgE level of the peanut extract were lacking in 13% of 
the samples analysed all commercially available peanut allergens. However, only three 
of these 13 children reported symptoms to peanut and no had symptoms of a systemic 
reaction. The immunoblot which was performed in serum from one study subject with a 
systemic reaction at challenge indicated major sensitization to a peanut protein of 
unknown identity (paper V). Future analyses of sera from symptomatic patients with 
unexplained peanut sensitization may provide evidence on the clinical relevance of this 
protein. 
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6 CLINICAL IMPLICATIONS 
During the years 2006-2012, the time of doctoral studies for my thesis, there has been a 
rapid development in the field of allergy diagnosis, in particular diagnosis of food 
allergy with the introduction of CRD. Our studies have contributed to this development 
and may have had an impact on clinical routines concerning diagnosing peanut allergy. 
Many children with peanut sensitization have until recently been advised to avoid 
peanuts because of risk of severe reactions. A major reason for this was the paper by 
Sampson H et al where they in 2001 showed that IgE above 15 kUA/L were associated 
with a risk of severe reactions. Today, determination of peanut allergen IgE 
components, in combination with a careful taken clinical history, may help to 
disentangle children at risk of severe reactions from children with asymptomatic birch 
pollen cross-reactive sensitization. According to our own data about one third of peanut 
sensitized children in Sweden should possibly be able to eat peanuts without fear of 
severe reactions. 
 
From the results of this thesis I have learned that:  
 
- In a population based material of young children sensitization to birch pollen 
and cat are most prevalent. However, in early school age the prevalence of 
sensitization to timothy pollen and dog have almost become similar to that of 
birch pollen and cat which has not been described before. 
 
- Ara h 2 sensitization, especially in combination with sensitization to Ara h 1 
and/or Ara h 3, is often associated with clinical peanut allergy.  
 
- Isolated Ara h 8 sensitization seems to indicate peanut tolerance in most cases. 
In such patients who are avoiding peanuts, this food item may be introduced 
cautiously at home in order to avoid unexpected severe reactions. The reason 
for this cautious introduction is the possibility of sensitisation to still not 
characterized peanut allergen components. 
 
- Ara h 6 cross-reacts extensively with Ara h 2. In rare cases Ara h 6 
sensitization may occur in the absence of Ara h 2 sensitization and thereby 
cause a severe reaction at exposure to peanut. Therefore, it must be very 
useful to have Ara h 6 commercially available. 
 
- When analysing test results for peanut components, the sum of IgE to peanut 
components should at least cover the IgE level of the peanut extract. When 
peanut extract IgE levels are increasing it should be accompanied with a 
corresponding increase in peanut component IgE. If not, this should be a sign 
for increased awareness since patients, even though rarely, may be sensitized 
to peanut allergen components not yet characterized.  
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- A previous history of a systemic reaction at peanut exposure should always be 
seriously considered when assessing the risk of a systemic reaction at 
challenge, irrespective of IgE test results. The reason for this is that all peanut 
proteins related to IgE-mediated reactions may not yet have been identified 
and characterized. 
 
 
- With the use of CRD, we are now hopefully heading towards less restrictive 
advices on elimination of foods from the diet in a substantial number of birch 
pollen allergic patients. The difficulties to disentangle harmless reactions from 
harmful will hopefully be reduced by using allergen component testing.  
 44 
7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Allergisjukdomar är en av våra största folksjukdomar och ca 25% av alla barn i Sverige 
har någon form av allergibesvär. Allergirelaterade sjukdomar har ökat under flera 
decennier, men ökningen verkar ha planat ut i vissa delar av västvärlden samtidigt som 
vi ser en ökning i t.ex. Östeuropa och delar av Asien.  
 
Att vara allergisk innebär för de flesta att deras immunförsvar reagerar mot ett i vanliga 
fall ofarligt ämne. Vid kontakt med ämnet bildas så kallade allergi-antikroppar – 
Immunoglobulin E (IgE). Denna process benämns sensibilisering. Det 
allergiframkallande ämnet kallas allergen. Allergenet kan t ex vara proteiner i pollen 
som når kroppen via inandningsluften eller proteiner i ett födoämne som hamnar i mag-
tarmsystemet. En allergisk reaktion triggas igång vid förnyad kontakt med allergenet 
och visar sig i form av astma, hösnuva, eksem, nässelutslag, svullnader, magbesvär 
eller i värsta fall allergisk chock som kan vara ett livshotande tillstånd. 
 
Allergier mot mat är vanliga framförallt under barndomen. Beroende på hur denna 
allergiform definieras så drabbas ca 2%-10 % av befolkningen. Jordnötsallergi är en av 
de vanligaste formerna av födoämnesallergier och en viktig orsak till allvarliga 
allergiska reaktioner. Förekomsten i befolkningen varierar mellan 0.6 % och 3 % i olika 
undersökningar och flera studier pekar på en ökande trend det senaste decenniet.  
 
Korsreaktioner mot födoämnen är mycket vanliga hos personer med pollenallergi. 
Orsaken är att många födoämnen och pollen innehåller liknande proteinstrukturer. 
Pollen-IgE-antikroppar korsreagerar mot allergen i födoämnen på grund av likheterna i 
struktur. Följden blir att den som är pollensensibiliserad också kan vara sensibiliserad 
mot olika födoämnen. Beroende på hur lika dessa proteiner är varandra så kan symtom 
uppkomma vid förtäring av födoämnet. I regel blir dessa symtom lindriga och 
begränsade till munhålan. Serologisk korsreaktion, kanske bättre benämnd 
korssensibilisering, föreligger ofta utan att några som helst symtom uppkommer vid 
förtäring av födoämnet i fråga. Det positiva IgE-testet mot födoämnet kan i onödan 
orsaka oro för att drabbas av allvarliga reaktioner. 
 
Det övergripande syftet med denna avhandling var att studera sensibiliseringsmönster, 
d.v.s. förekomsten av IgE antikroppar, mot luftburna allergen under barndomen. 
Dessutom att studera björkpollen- och jordnöts-antikroppar samt antikroppar mot olika 
strukturer i jordnöt i relation till symtom på jordnötsallergi. 
 
Studierna baseras till största delen på material från BAMSE-studien (Barn, Allergi, 
Miljö i Stockholm, en Epidemiologisk studie); en undersökning med fokus på att 
studera utveckling av allergisjukdomar innefattande drygt 4000 barn som följs sedan 
födseln i början av 1990-talet. Den sista delstudien i avhandlingen är utförd på 
Sachsska Barnsjukhuset och inkluderade 98 barn från allergimottagningen samt 62 barn 
från BAMSE-studien. 
 
I den första studien beskrevs sensibilisering mot allergiframkallande ämnen i luften, 
främst pollen och pälsdjur, mellan fyra och åtta års ålder. Vi konstaterade att det är en 
mycket dynamisk process där andelen sensibiliserade barn ökade från 15 % till 25 % 
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mellan fyra och åtta års ålder samt att antikroppar mot björkpollen och katt dominerade. 
Ökningen i förekomst av sensibilisering mot timotej och hund var dock relativt sett 
större och verkade ”knappa in” på förekomsten av sensibilisering för björkpollen och 
katt. 
 
I studie 2 visade vi att åttaåringar som var sensibiliserade mot både björkpollen och 
jordnöt i mindre utsträckning uppgav symtom vid förtäring av jordnötter jämfört med 
åttaåringar som var sensibiliserade mot jordnöt men inte mot björkpollen. Detta 
tvärtemot vad man skulle tro eftersom IgE mot flera olika ämnen brukar resultera i 
högre förekomst av allergisymtom.  
 
I den tredje studien ville vi titta närmare på orsakerna till fynden i studie 2 och 
analyserade IgE-allergena komponenter mot pollen och jordnöt. Allergena 
komponenter är de olika molekyler, framför allt proteinmolekyler i t.ex. ett födoämne 
som kan ge upphov till allergiantikroppar (IgE). Nomenklaturen vid komponentanalys 
bygger på det latinska namnet för växten eller djuret i fråga samt i vilken ordning 
proteinet karakteriserades. För jordnöt (Arachis hypogaea) får allergena komponenter 
de tre första bokstäverna från familjenamnet (Ara) och den första bokstaven från 
artnamnet (h). Allergisk sensibilisering för jordnötskomponenterna Ara h 1, Ara h 2 
och Ara h 3 anses vara de proteinmolekyler som ger upphov till ”äkta” jordnötsallergi 
medan sensibilisering för den björkpollen-liknande komponenten Ara h 8 ses vid 
samtidig sensibilisering för björkpollen p.g.a. den serologiska korsreaktionen mellan 
Ara h 8 och huvudallergenet i björkpollen. Vi kunde konstatera att Ara h 2-IgE var 
starkast kopplad till symtom mot jordnöt, särskilt i kombination med IgE mot Ara h 1 
och/eller Ara h 3. De barn som var sensibiliserade mot Ara h 8 och inte mot Ara h 1, h 
2 eller h 3 angav jordnötssymtom i lägre utsträckning och angav betydligt lindrigare 
symtom. Resultaten tydde alltså på att antikroppar mot Ara h 8 kunde ses som 
indikation på att symtom från jordnöt endast blev lindriga eller att inga symtom 
uppträdde alls. 
 
Det fjärde delarbetet i avhandlingen är en fallbeskrivning av en 15-årig pojke som fick 
en anafylaxi efter en jordnötsprovokation på Sachsska barnsjukhuset, trots låga nivåer 
av jordnötskomponenterna Ara h 1, h 2 och h 3. Analys av allergiantikroppar visade 
höga nivåer mot jordnötskomponenten Ara h 6 som är mycket lik Ara h 2 i sin 
proteinstruktur. IgE mot Ara h 6 finns sällan i blodet utan samtidig förekomst av 
allergiantikroppar mot Ara h 2. Så var det dock inte i detta sällsynta fall. 
 
I studie 5 ville vi testa hypotesen att vid sensibilisering mot jordnöt, men bara 
förekomst av Ara h 8 antikroppar, uppstår inte allvarliga reaktioner mot jordnöt. Vi 
gjorde detta genom att utföra jordnötsprovokationer på barn som ”bara var Ara h 8”-
sensibiliserade. De fick äta jordnötter under kontrollerade former på Sachsska 
barnsjukhuset. Nästan alla dessa barn tålde jordnöt eller fick snabbt övergående klåda i 
munnen. En pojke som reagerat mot jordnöt tidigare i livet fick en kraftig allergisk 
reaktion vid jordnötsprovokationen i vår studie. En specialanalys av hans IgE-
antikroppar, så kallad immunoblotting, visade att nästan allt jordnöts-IgE var riktat mot 
ett hittills okänt jordnötsprotein. Troligtvis var det IgE mot detta ännu inte 
karaktäriserade jordnötsprotein som gav upphov till reaktionen. 
 
 46 
Sammanfattningsvis talar resultaten för att sensibilisering mot luftburna allergen under 
barndomsåren är en dynamisk process och att björkpollensensibilisering dominerar vid 
åtta års ålder. Korsreaktioner mot den björkrelaterade jordnötskomponenten Ara h 8 är 
sannolikt inte kopplade till svåra allergiska reaktioner vid jordnötsexponering, men det 
är viktigt att vara vaksam för att hittills okända allergiframkallande 
jordnötskomponenter i mycket sällsynta fall kan framkalla sensibilisering och 
reaktioner. Varningstecken är en sjukhistoria med uppgifter om tidigare allvarlig 
reaktion mot jordnöt eller stigande IgE mot jordnötsextrakt utan motsvarande stegring 
av IgE mot kända jordnöts-komponenter. 
 
Ca 1/3 av de barn i Sverige som har jordnötsantikroppar i blodet har bara typen Ara h 8. 
I princip samtliga barn med jordnötsantikroppar i blodet har hittills fått rådet att helt 
undvika jordnötter av rädsla för allvarliga reaktioner. Den ökade kunskapen kommer 
underlätta diagnostiken av jordnötsallergi och minska lidandet hos många 
jordnötssensibiliserade barn som inte längre behöver oroa sig för allvarliga 
jordnötsreaktioner. 
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